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ABSTRACT 
Metabolism of xenobiotics remains a central challenge for the discovery and 
development of drugs, cosmetics, nutritional supplements and agrochemicals. 
Metabolic transformations are frequently related to the incidence of toxic effects 
which may result from the emergence of reactive species, the systemic accumulation 
of metabolites or by induction of metabolic pathways. Experimental investigation of 
the metabolism of small organic molecules is particularly resource demanding, hence 
computational methods are of considerable interest to complement experimental 
approaches. 
This review provides a broad overview of structure- and ligand-based 
computational methods for the prediction of xenobiotic metabolism. Current 
computational approaches to address xenobiotic metabolism are discussed from three 
major perspectives i) prediction of sites of metabolism (SOMs), ii) elucidation of 
potential metabolites and their chemical structures and iii) prediction of direct and 
indirect effects of xenobiotics on metabolizing enzymes, where the focus is on the 
cytochrome P450 (CYP) superfamily of enzymes, the cardinal xenobiotics 
metabolizing enzymes.  
For each of these domains, a variety of approaches and their applications are 
systematically reviewed, including expert systems, data mining approaches, 
quantitative structure-activity relationships (QSARs) and machine learning-based 
methods, pharmacophore-based algorithms, shape-focused techniques, molecular 
interaction fields (MIFs), reactivity-focused techniques, protein-ligand docking, 
molecular dynamics (MD) simulations and combinations of methods. 
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Predictive metabolism is a developing area and there is still enormous potential for 
improvement. However it is clear that the combination of rapidly increasing amounts 
of available ligand- and structure-related experimental data (in particular, quantitative 
data) with novel and diverse simulation and modeling approaches is accelerating the 
development of effective tools for prediction of in-vivo metabolism, which is 
reflected by the diverse and comprehensive data sources and methods for metabolism 
prediction reviewed here. This review attempts to survey the range and scope of 
computational methods applied to metabolism prediction and also to compare and 
contrast their applicability and performance. 
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INTRODUCTION 
In the discovery and development of new medicines, attrition rates are still very 
significant, despite the comprehensive measures taken by the chemical and 
pharmaceutical industry to lower the risk of failure. In pharmaceuticals, toxicity is a 
major contributor to the withdrawal of new drugs and often the underlying biological 
mechanism of toxicity is related to metabolism. Metabolic liability is not only a safety 
concern for drugs but is also highly relevant to a host of industries including 
nutritional supplements, cosmetics or agrochemicals (basically any situation in which 
biology is exposed to chemistry).1, 2 
Metabolic liability can lead to a number of diverse issues, for example drug-drug 
interactions (DDIs),3 including enzyme inhibition, induction and mechanism-based 
inactivation,4 resulting in substantial variations (one or more orders of magnitude) of 
drug concentrations present at target and anti-target sites.5 These effects potentially 
lead to a loss of pharmacological efficacy due to enhanced clearance or toxic effects 
caused by accumulation. DDIs may also increase the rate of reactive, toxic 
intermediates formed.6, 7 The more the metabolism of a drug is specific to one 
enzyme, the more likely is the occurrence of DDIs. 
DDIs caused by monoamine oxidase (MAO) inhibition often limit the co-
administration of multiple drugs. This is problematic in the case of depression and 
infections, where co-administration of drugs is common.8 Because of potentially 
lethal dietary and drug interactions, monoamine oxidase inhibitors have historically 
been reserved as a last line of treatment, used only when other classes of 
antidepressant drugs such as selective serotonin reuptake inhibitors and tricyclic 
antidepressants have failed. Tyramine metabolism can be compromised by dosing of 
MAO inhibitors, and in the case of dietary intake of large amounts of tyramine (e.g. 
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aged cheese9) one theory is that tyramine displaces norepinephrine from the storage 
vesicles and may result in a cascade in which excess norepinephrine is released giving 
a hypertensive crisis. Many drugs are potentially lethal if ingested with MAO 
inhibitors. For example tryptamines, co-administered with an MAO inhibitor, can 
reach very high concentrations and result in serotonin syndrome.10 The co-
administration of drugs which are metabolized by MAOs requires great care as they 
may in combination saturate the capacity of MAO for metabolism, resulting in altered 
pharmacokinetics of the drugs and very high concentrations can be reached on 
multiple dosing. Another example is change of behavior, where transient behavioral 
sensitization to nicotine becomes long-lasting with addition of MAO inhibitors.11 
Metabolic reactions may also be systematically exploited in drug design to optimize 
ADME and toxicity properties following a prodrug concept.12 It may remain unclear 
whether the parent molecule is responsible for the entirety of the pharmacological 
effects observed or if one or several of its metabolites are contributing to the desired 
therapeutic effect. Another aspect to consider is that for a metabolism-activated 
prodrug, inhibition of the enzyme required for its activation may cause a loss of 
pharmacological efficacy or induce toxicity. 
Identification of sites of metabolism (SOMs) on molecules and the structure of their 
metabolites can be decisive for the design of molecules with favorable metabolic 
properties. Medicinal chemistry driven ADME optimization programs can thus 
systematically address vulnerabilities in proposed drug molecules (Figure 1). 
However, experimental techniques to detect and quantify DDIs, as well as to 
determine SOMs and structures of metabolites are still highly resource-demanding 
and challenging,13 which is why in recent years, substantial efforts have been applied 
to develop computational approaches to predict these metabolic outcomes. 
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In this review, we begin with a general perspective of the scope of ligand-based and 
structure-based methods for the prediction of xenobiotic metabolism. We then provide 
an overview of recent developments in computational methods for predicting: 
(i) SOMs, 
(ii) structures of potential metabolites, 
(ii) interactions of small molecules with metabolizing enzymes and metabolic 
pathways, focusing on CYPs. This section also includes a comprehensive 
overview on structure and MD (molecular dynamics) simulations of this 
enzyme superfamily. 
We conclude with a perspective and outlook on the scope and limitations of in 
silico methods for the prediction of xenobiotic metabolism. 
Overviews of computational methods discussed in this work are provided in Table 1 
and Figure 2. 
 
LIGAND-BASED AND STRUCTURE-BASED METHODS FOR PREDICTING 
XENOBIOTIC METABOLISM 
Computational techniques for predicting xenobiotic metabolism can be classified 
into ligand-based and structure-based approaches. In the first approach, structures of 
known active and inactive compounds may be modeled to derive structure-activity 
relationships (SARs, where “activity” refers to a measure of metabolism) and other 
properties such as SOMs, etc. In the second approach, efforts are focused on the 
properties of the metabolizing enzyme itself, its interactions with the ligand, and the 
mechanism of the reaction. 
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Ligand-based methods need to deal with significant uncertainties about the binding 
site environment of a metabolizing enzyme, in comparison to structure-based 
approaches, since the properties of the proximate target environment a ligand binds to 
may remain largely speculative if no structural data are available. Minor 
modifications of the ligand may lead to clashes with the protein and, hence, to a loss 
of bioactivity. However, for ADME processes, small changes in ligand structure do 
not typically result in major changes in metabolism, presumably due to the flexibility 
of the metabolizing enzyme active sites. 
There is increasing interest in methods considering the molecular shape of both 
ligands and enzyme active sites. While pharmacophoric interaction patterns have long 
been established as a major factor for bioactivity, in recent years methods for the 
inclusion of molecular shape as a key component for molecular recognition have 
gained popularity. Besides metabolism prediction, shape-based methods are also 
applied in many areas of computational drug discovery such as protein active site 
comparisons, virtual screening and lead optimization. 
Of course the relative utility of ligand-based and structure-based computational 
approaches is not as imbalanced as it may seem in the first instance. The substantially 
higher level of complexity introduced by the consideration of macromolecular 
structures raises demands in computational power, expert knowledge and manual 
interaction, as well as reliance on the phenomenological descriptions of the protein, 
the ligand and their environment. 
In general, structure-based methods have focused on deriving patterns from static 
structures of protein-ligand complexes without considering time-dependent 
conformational fluctuations, unless combined with even more resource-intensive MD 
simulations or similar methodologies (see the section on “Molecular dynamics 
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simulations on the structure of CYPs”). Receptor-ligand conformations observed in 
X-ray crystallographic experiments may include crystal packing effects and other 
experimental uncertainties.14 Also, an observed ligand pose may not necessarily 
reflect the relevant binding mode for the metabolic transformation. 
 Structure-based methods that predict receptor-ligand binding geometry (e.g. for 
SOM prediction) should ideally take some of the changing properties upon 
complexation of both the ligand, the protein and the ligand/protein complex into 
consideration. For example, desolvation and entropic components often play a 
dominant role in the energetics and geometry of ligand binding, however both 
desolvation and entropic effects are difficult to model accurately (including diffusion, 
on-off rates and solvent reorganization). The approximations necessary to enable 
predictions to be made in a reasonable time-scale are significant. Additionally, ligands 
typically approach a binding/active site through a size-limiting access channel and it 
is non-trivial for structure-based approaches to simulate the dynamic changes in 
geometry required for the approach of the ligand to the binding site. Ligands that are 
metabolized, however, may be assumed to include all these properties, which to some 
degree are intrinsically included in ligand-based models. 
Despite the challenges structure-based methods have significantly contributed to the 
rationalization of metabolic reactions and with rapidly advancing technologies for 
structure elucidation and computation of dynamics and reactivity structure-based 
methods are becoming ever more predictive and accurate. Certainly, the combination 
of both ligand-based and structure-based approaches is most promising, leading to 
synergistic effects between different algorithmic approaches that allow more 
comprehensive descriptions of metabolic reactions. 
PREDICTING SITES OF METABOLISM 
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Identifying SOMs of a molecule may give decisive hints in the development of a 
medicinal chemistry strategy to optimize metabolic properties and, consequently, 
crucial parameters such as toxicity, bioavailability and bioactivity. Chemical 
reactivity and orientation of the ligand bound to the catalytic site of the enzyme are 
key for the location of SOMs. 
Today, a plethora of computational approaches are available, which attempt to 
identify the most likely SOMs. Algorithms include reactivity-based approaches, 
fingerprint-based data mining approaches, shape-focused techniques, molecular 
interaction fields (MIFs), protein-ligand docking and combinations of methods 
(Figure 2). Most of the techniques available to date consider a single aspect of 
metabolic reactions, such as the reaction energy barrier, geometrical properties or 
pharmacokinetic properties for predicting SOMs or potential metabolites.13 In reality 
however, a combination of factors (energetics, geometry, reaction mechanism etc.) is 
decisive for a metabolic reaction to take place and hence combined approaches render 
a more realistic and more accurate view of biotransformations. 
To quantify the SOM prediction performance of an algorithm it is usually tested on 
a set of compounds for which at least one SOM has already been identified 
experimentally. Many testing protocols use the “Top-N” metric, which for a given 
compound is the occurrence of an experimentally confirmed SOM within the N top-
ranked predicted SOMs. A major insufficiency of this metric is that it does not 
account for the fact that for some substrates the prediction of a SOM may be biased. 
This metric is for example strongly influenced by the size of a molecule, as larger 
molecules intrinsically have more putative SOMs. More recently, the “Lift” metric 
has been introduced in order to overcome this bias.15 This measure includes the 
prediction accuracy of a computed model compared to a random model. 
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Reactivity-based approaches 
Reactivity-based approaches utilize descriptors that are derived from the electronic 
structure of the molecule to predict its liability for metabolic transformations (see 
“Reactivity of CYPs” for more information on the reaction mechanism of CYPs). For 
computational efficiency, semi-empirical quantum mechanical methods can be used. 
As a preamble to the main calculation, a 2D-representation of a ligand must be 
converted to a 3D representation and the correct hydrogen addition performed 
considering tautomeric states and pKa values of ionizable groups, followed by 
geometry optimization. 
QMBO16 estimates hydrogen abstraction energies based on bond order. Starting 
with the premise that the hydrogen abstraction by Compound I (see “Reactivity of 
CYPs”) from a substrate is the rate-limiting step, the method relates the reactivity of 
each hydrogen atom to the strength of its covalent bond. Using a wavefunction 
generated from density functional theory (DFT), bond orders for all C-H bonds in a 
substrate are calculated, and then normalized. Bond strength is correlated to 
deviations from average bond orders. Corrections are made for buried hydrogen 
atoms through scaling by a factor that is a function of the solvent accessible surface 
area (SASA) of the hydrogen atom.  
Given that the highly electrophilic Compound I has received an electron from the 
substrate, the substrate will form a positively charged radical intermediate, and where 
this spin hole is localized, there will be a likely SOM. Using a DFT wavefunction, the 
QMSpin16 tool calculates spin densities on all hydrogen atoms using Fermi contact 
values. The same SASA scaling approach used in QMBO is applied. Of these two 
methods, QMBO is reported to perform slightly better than QMSpin. Using the Top-3 
metric for SOMs over 81 molecules, QMBO predicts 84% and QMSpin 78%.16 
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CypScore17 makes use of a range of atomic reactivity descriptors generated from an 
AM118 wavefunction, with molecular properties derived from this using the software 
VAMP19 and ParaSurf.20 These descriptors are used for the generation of individual 
models for the most important reactions catalyzed by CYPs. Using the Top-3 metric, 
87% of SOMs were identified from a test set of 39 molecules. 
Most reactivity-based approaches put substantial weight on correction factors often 
related to topological properties describing accessibility. These are discussed in the 
section “Combined approaches” below. 
Fingerprint-based data mining approaches 
Fingerprint-based data mining approaches describe the presence or absence of 
chemical features within a molecule and relate these to metabolic reaction sites and 
products. The chemical environment of a SOM is associated with a fingerprint 
descriptor enabling predictions to be made about novel compounds by searching for 
locations with the same or similar fingerprint within the target molecule. The relative 
likelihood of a fingerprint being associated with a SOM can be calculated from the 
number of occurrences of this transformation and the method can be trained on a 
dataset of known metabolic transformations. This can suggest a ranking for different 
sites within a molecule according to their likelihood of being a SOM. 
Metaprint2D21-24 is a data-mining tool, which identifies SOMs based on circular 
fingerprints. The software package is Java-based and an online service25 allowing 
prediction of SOMs for uploaded or drawn structures is available. Metaprint2D mines 
large biotransformation databases such as the Accelrys Metabolite Database,26 which 
contains more than 100,000 metabolic transformations. For each atom of each 
substrate-metabolite pair included in the database, the atom type at the SOM, as well 
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as its proximate environment is encoded in a fingerprint. In order to derive 
probabilities for a specific atom to be involved in a metabolic interaction, the 
occurrence of each of the encoded atom environments is calculated and compared to 
the number of biotransformations recorded in the database for this particular atom 
environment. The normalized occurrence ratio does not reflect the absolute 
probability of a metabolic reaction to occur, but can indicate the prevalence of a 
reported transformation in the literature. The Metaprint2D algorithm uses a memory 
cache to store the fingerprints, allowing results to be returned in under a second. A 
disadvantage of this data mining approach is that predictions cannot be made about 
novel atomic sites where the fingerprint does not exist in the dataset. MetaPrint2D 
detects novel sites within a query molecule and acknowledges that they are outside 
the applicability domain when it presents the metabolic predictions in its graphical 
results output. 
Tests of the method using compounds added to later versions of the Accelrys 
Metabolite Database (other than that used for model training) indicate that SOMs are 
correctly predicted in about 70-80% of cases among the top-3 highest-scored atom 
positions.21  
Metaprint2D-React21 is an extension of MetaPrint2D that allows prediction of 
metabolic products based on the structure of a substrate (see “Predicting Xenobiotic 
Metabolites”). The metabolites proposed by MetaPrint2D-React are ranked according 
to the relative occurrence of matching transformations in the training database 
associated with that fingerprint pattern. A freely accessible online version of the 
software is available.27 
Machine-learning approaches 
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SOM prediction methods based on machine learning methods such as support 
vector machines (SVMs) and artificial neural networks (ANNs) have recently gained 
more attention for use in SOM prediction. Simulations Plus have introduced the 
Metabolite Prediction module28 to their ADMET Predictor software. Like 
MetaPrint2D, this prediction tool is trained on the Accelrys Metabolite Database. This 
dataset has been curated and some further sources for metabolic reactions were added. 
Models for the prediction of SOMs are based on artificial neural network ensembles 
(ANNEs) derived using atomic descriptors to generate an artificial neural network 
classification (ANNC) model. For each atom of a molecule a score (0-1) for the 
likelihood of a metabolic reaction to happen is assigned. In addition to that, a 
substrate classification model can predict whether a compound is a substrate of five 
CYP isoforms.  
Further examples include combined approaches, which are discussed in the section 
“Combined approaches” below. 
Shape-focused approaches 
The concept of shape-focused methods is based on the observation that compounds 
sharing a similar shape have a high probability of binding to the same receptor. The 
shape of a ligand is thought to resemble the partial complementary shape of the 
binding site. In this way, shape-focused methods attempt to identify bioactive 
molecules by molecular shape recognition. Shape similarity between the bioactive 
template molecule superimposed upon a candidate molecule is used for a quantitative 
calculation of the likelihood for metabolism, with the site identified from the 
proximity to the experimentally determined site on the template molecule. 
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Shape-based methods can be effective and have become increasingly popular in the 
area of similarity-based virtual screening29-34 and bioactivity profiling.35 Shape-
focused methods are advanced versions of shape-based methods, where alignment and 
ranking are performed using a chemistry-aware algorithm. The inclusion of chemical 
information (resembling pharmacophoric constraints) to molecular shape can be an 
additional factor in improving the accuracy of these methods.30 
The shape-focused screening method Rapid Overlay of Chemical Structures 
(ROCS)36 was employed to predict the SOM of CYP2C9 substrates.37 Flurbiprofen, a 
substrate of CYP2C9 that is hydroxylated by the enzyme at position 4’, was extracted 
in a protein-bound conformation from an X-ray structure for use as a structural 
template for a ROCS search. The assumption was that the SOM of any CYP2C9 
substrate should be located in proximity to the SOM of flurbiprofen. ROCS was 
employed to superimpose 70 known CYP2C9 substrates to the flurbiprofen template 
and encouraging results were found: The SOMs of 60% of all investigated molecules 
were positioned within 3 Å of the 4’-hydroxylation site of flurbiprofen, with 39 (89%) 
out of the 44 top-ranked molecules correctly predicted. Additionally, alignments were 
further analyzed including the protein background to evaluate whether the positioning 
of the SOM also relates to the heme iron. The average distance between the known 
SOM and the heme iron was found to be 5.21±0.95 Å, which is in agreement with 
experimentally observed substrate-heme distances. The approach is rapid, largely 
unbiased and does not require manual interaction, which allows large-scale profiling 
of drugs and other similar molecules to a defined substrate. 
Molecular interaction fields 
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Molecular interaction fields (MIFs) are one of the most established and most 
versatile concepts in drug discovery. The idea of MIFs is to encode the variation of 
interaction energies between a target molecule and a chemical probe in 3D space. The 
probes are usually an atom, a point charge or a molecular fragment and depending on 
the physicochemical properties of the probe, distinct characteristics about the target 
molecule can be derived from the calculated interaction energies. 
In ligand-based design, MIFs may be used to derive 3D-QSAR models and 
pharmacophoric representations and to predict pharmacokinetic parameters such as 
cell permeability and metabolism. In structure-based research they are employed to 
analyze structural features of macromolecules such as protein-ligand and protein-
protein interfaces. MIFs have been reported to be useful to elucidate information for 
rational drug design on how to optimize protein-ligand interactions, areas of ligands 
vulnerable to metabolism and ligand/isoform specificity. There are currently a number 
of implementations of MIFs in CYP-related metabolism of xenobiotics and examples 
covering many of these aspects have been published (as discussed in the following 
and in “Predicting interaction of xenobiotics with CYPs”). 
GRID38 has been developed as a tool to explore and characterize protein structures 
for areas favorable for interaction with small organic molecules. The software is well 
known for its key role in the design of the anti-influenza drug zanamivir.39 Common 
probes in GRID include DRY (representing hydrophobic interactions), N1 
(representing hydrogen bond donors, derived from planar NH such as amides) and O 
(representing hydrogen bond acceptors derived from a sp2 carbonyl oxygen). 
An example of a MIF-based software package for predicting SOMs is MetaSite.40 
Further approaches utilizing MIFs have been reported, in general combined with other 
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computational techniques. For more detail on these approaches the reader is referred 
to “Combined approaches”. 
Protein-ligand docking 
Protein-ligand docking has become an integral part of today’s rational lead 
identification and optimization process. By 2004 it is estimated that about 50 new 
entities had reached clinical trials and/or market approval guided by structure-based 
drug design.41 With crystal structures available for the major human CYP isoforms, 
protein-ligand docking is showing promise for the analysis and prediction of CYP-
induced metabolism.7 
Docking consists of two parts. First, the ligand is docked into the receptor binding 
site. This is the actual docking process and involves sampling the conformational 
space of the ligand within the binding site. In the second step, the generated docking 
poses are evaluated and some measure of affinity or the fit of the ligand for the 
receptor is estimated. This step is also referred to as scoring. 
By using protein structures directly as model systems, docking is largely unbiased 
by known SAR, offering opportunities to reveal entirely new binding modes. Current 
ligand docking methods are limited by many approximations including approximate 
descriptions of desolvation, entropic and enthalpic components as well as dynamic 
structural changes of the protein upon ligand binding. Generally the faster the method, 
the more significant are the approximations made. Packing forces also introduce bias 
to the model. Ligand-induced mobility of the binding site becomes apparent when 
comparing re-docking with cross-docking results. In the first case, a docking 
algorithm is used to re-dock a ligand extracted from the binding pocket (no induced 
fit) while in the latter case, ligands are cross-docked to target structures derived from 
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protein structures templated to an alternative ligand. Cross-docking in general shows 
significantly lower accuracy compared to re-docking. The reasons for this include the 
conformational changes induced in both the protein and ligand.42 
Docking may allow the derivation of SOMs by relating the proximity of ligand 
atoms of a docking pose to the catalytic center of the enzyme. Additionally, docking 
also allows investigation of binding properties of ligands to their target proteins and 
suggests SAR (see “Predicting interaction of xenobiotics with CYPs”). Direct 
consideration of the protein environment allows the elucidation of residues involved 
in ligand binding and can allow rationalization of different metabolic properties of 
enantiomers by analysis of the protein-ligand interactions. This information is 
valuable for the design and optimization of drug candidates. 
Generally speaking, current docking algorithms offer adequate performance for 
elucidating the ligand-binding mode provided an appropriately complimentary (to the 
ligand binding pose) protein structure is applied that covers the relevant receptor 
conformation. Cross-docking still poses significant problems. Despite decades of 
research, some cardinal issues of docking -and in particular of scoring- have not yet 
been resolved.7 Key aspects such as diffusion, entropy and solvation effects remain 
largely neglected by scoring functions.43 
A systematic investigation of the impact of water molecules present/absent in the 
active site of 19 CYP structures44 has been reported for AutoDock,45 FlexX,46 and 
Genetic Optimization for Ligand Docking (GOLD).47 Performance was compared for 
the process of docking into water-free binding sites, binding sites with 
crystallographic water present, and binding sites with water molecules placed using 
GRID. It was found that the consideration of crystallographic water molecules 
generally improves the docking accuracy of all three approaches and that the 
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introduction of water molecules predicted with GRID leads to a further increase of 
accuracy with regard to root mean square deviations (RMSDs) of the docked ligand 
from the experimentally determined position and SOM prediction accuracy. 
In a follow-up study focusing on CYP2D6, considering several different scenarios 
for the inclusion of water, it was confirmed that the placement of water molecules 
almost always leads to an increase in docking accuracy.48 Correctly placed water 
molecules improve docking-based SOM prediction (as well as virtual screening 
accuracy). The combination of GOLD with ChemScore49 was found to perform 
particularly well. 
Recently, Santos et al.50 systematically investigated the impact of water molecules 
on protein-ligand docking of substrates of CYP2D6. Representative protein 
conformations used for docking were generated using MD simulations of an X-ray 
structure of (R)-3,4-methylenedioxy-N-ethylamphetamine (MDEA) bound to 
CYP2D6. Hydration sites were derived from the trajectory and water molecules were 
placed at the computed positions for water in the protein frames used for docking. 
Eleven substrates similar to MDEA and 53 structurally distinct compounds were then 
docked into the representative protein conformations. These results indicated that 
water molecules placed into the binding site might have a beneficial impact on the 
docking performance of substrates closely related to the crystallographically 
determined ligand. However, this effect is strongly dependent on the protein and 
ligand conformation. Also, there seemed to be no benefit from the inclusion of MD-
derived water molecules for substrates dissimilar to MDEA. Overall, in this case, 
water molecules were found rather weakly bound inside the CYP2D6 binding pocket, 
with an average residence time below 10 ps, which may contribute to the lack of 
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beneficial effect on inclusion of specific water on docking and the observed substrate 
promiscuity of the enzyme. 
Examples of the successful prediction of SOMs include a study by Vasanthanathan 
et al.,51 who performed docking experiments on CYP1A2 employing GOLD with 
various docking scenarios. These scenarios differed in the treatment of the 
crystallographic water molecules mediating a hydrogen bond between the enzyme and 
the ligand and in the scoring function used (ChemScore or GOLDScore). Docking 
was deemed successful if the known SOM of a docking pose was computed to be 
within a 6 Å radius from the heme iron. While docking performed adequately to allow 
the elucidation of binding orientations and conformations of ligands as well as 
moderate enrichment rates during virtual screening, superior performance in 
classifying individual compounds into those that were, or were not metabolized, was 
observed for machine learning methods (reviewed later). In contrast to several other 
docking studies on CYPs, the authors did not detect a significant benefit from 
including water molecules in protein-ligand docking (see below). 
Unwalla et al.52 used Grid-based LIgand Docking with Energetics (GLIDE)53 and a 
homology model for CYP2D6 to predict the SOMs of 16 substrates. Predictions were 
deemed correct if the known SOM is located less than 4.5 Å from the catalytic iron 
among the five top-ranked docking poses, which was the case for 85% of all 
investigated cases. Docking results obtained from this CYP2C5-derived homology 
model were significantly better correlated to the experiment than docking results 
obtained from a X-ray structure of apo CYP2D6. 
Scoring ligand interactions with the heme prosthetic group is challenging, requiring 
specific parameterized scoring functions. Extensive hydrophobic surface areas which 
are present in CYPs contribute to the difficulty of docking ligands to this protein 
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family. The lack of strong, directed hydrogen bonding interactions makes scoring 
functions highly dependent on the interpretation of weak van der Waals interactions 
between the ligand and the enzyme surface. 
With today’s computer hardware, computational resources are hardly an issue for 
most docking methods. A significant cost factor of docking is the degree of expert 
knowledge on the target under investigation and the interpretation of results from 
docking algorithm itself - not only during setup, but also during final data analysis. 
Relatively sparse coverage of structural information on CYPs (they are 
conformationally labile) limits the applicability of docking for this enzyme family. 
Techniques to extend the scope of docking include homology modeling and MD 
simulations, as discussed in the following section. 
Combined approaches 
As pointed out above, chemical reactivity and accessibility are the decisive aspects 
for a metabolic reaction to take place. It would not be anticipated that a metabolic 
reaction would proceed at a highly reactive site of a molecule that, for steric reasons, 
cannot be oriented within the CYP to interact with the reaction center. In such a case, 
a method purely considering reactivity-related aspects is likely to fail. Consideration 
of both aspects is crucial, which is reflected in the variety of combined approaches 
that have been reported.13 
MetaSite is an integrated software package for predicting CYP-mediated 
metabolism.40 It evolved from earlier approaches combining GRID and ALMOND54, 
55 and includes several different components to predict SOMs: MIF-based modules 
for the analysis of protein and ligand characteristics and quantum-chemical and 
knowledge-based components to account for metabolic reactivity. The software 
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package encodes the characteristics of CYP enzymes in the form of a fingerprint that 
is independent of the initial conformation of side chains in order to account for 
protein adaption induced by ligand binding. Atoms of the small organic molecule 
under investigation are categorized by their GRID probe counterparts to reflect their 
hydrogen-bonding and charge capabilities as well as their hydrophobic characteristics. 
Subsequently, they are transformed into a distance-binned representation, resulting in 
a fingerprint for each GRID probe category. The descriptors of the CYP structure and 
of the ligand are then compared in order to quantify the exposure toward the catalytic 
heme moiety for any of the ligand atoms, which relates to the liability for metabolism. 
MetaSite includes a reactivity component that estimates the likelihood of a metabolic 
reaction based on molecular orbital calculations, estimating the energetic barrier of 
hydrogen bond abstraction. The overall susceptibility at a certain atom position is then 
derived from a probability function accounting for both accessibility and reactivity. 
Only atoms obtaining high values for both measures are considered likely to be 
involved in metabolic reactions. The software also includes a knowledge-based 
reaction mechanism component for weighting preferences for types of metabolic 
reactions for the individual CYP isoforms.56 
Results of a MetaSite analysis are reported as a histogram bar chart indicating the 
likelihood of metabolism for any of the ligand atoms. An interesting feature of 
MetaSite is the Partial Contribution plot, which indicates moieties of the compound 
that are expected to interact favorably with the CYP isoform under investigation. This 
can provide valuable hints on how to optimize the metabolic properties of a ligand.57 
A structure-based approach such as this is limited to enzymes where a protein 
structure or homology model is available. A drawback of MetaSite is that it reports 
only the relative likelihood for a specific metabolic reaction to occur at a certain atom 
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position. Results among different molecules cannot be directly compared. This is also 
the case for the Partial Contribution plot. 
The authors of MetaSite claim a success rate of 85% for tagging a known SOM 
among the top-2 ranked atom positions. It was successfully employed to identify the 
main metabolites of the angiotensin receptor antagonists lorsartan, candesartan, 
valsartan, and tasosartan.54 In a study by Zhou et al.,58 MetaSite was found to 
correctly predict the SOM among the three highest-ranked atom positions for 78% of 
the investigated compounds. A more recent study employed MetaSite for the 
identification of SOMs to support experimental mass-spectrometric metabolite 
identification.59 The SOM top-ranked by MetaSite were experimentally confirmed for 
55% of the analyzed compounds. The hit rate improved to 84% when considering the 
three top-ranked atom positions. 
De Groot et al.60 reported one of the earliest approaches combining several methods 
to pinpoint SOM. They employed ligand-based pharmacophores, homology modeling 
and molecular orbital calculations (AM118) to identify the SOM of substrates of 
CYP2D6. Based on the information gained from the three domains, the SOM of six 
out of eight investigated ligands could be correctly identified. 
Rydberg et al. have released an open-source, Java-based, SOM predictor called 
SMARTCyp61-63. This software package contains a database of pre-calculated DFT 
activation energies for various ligand fragments undergoing a CYP3A4-mediated 
transformation. SMARTCyp performs a lookup for a ligand using this database which 
contains SMiles ARbitrary Target Specification (SMARTS) based fragments which 
are matched, in conjunction with an accessibility descriptor, to provide a ranking of 
the SOM. Using the Top-2 metric, 76% of SOM are identified over a test set of 394 
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compounds. The tool is fast due to the pre-cached QM results. Most recently, 
SMARTCyp was extended to predict reactivities for CYP2D6.63 
StarDrop64 predicts SOM based on quantum chemical analyses of molecules. For 
each atom of a molecule a metabolic site liability, reflecting the potential metabolite 
formation, is computed. The metabolic site liability of a ligand atom is denoted by 
values between 0 and 1. This is derived from an estimate of the hydrogen abstraction, 
which is related to the enzyme decoupling rate. While the same quantum chemical 
module is used for all CYP isoforms, specificity is assessed by alignment of the query 
molecule to a ligand-based model derived from known substrates of the respective 
isoform. Also logP, which appears to influence CYP-mediated metabolism (see 
“Expert systems”), is taken into account. StarDrop was reported to give success rates 
comparable to SMARTCyp.62 More information on the performance of these tools is 
provided in Ref. 15. 
RegioSelectivity (RS)-predictor15 is a recently released, isoform-specific approach 
to predict SOM. It utilizes 148 topological and 392 quantum chemical atom-specific 
descriptors, a support vector machine (SVM)-based ranking and multiple instance 
learning method. Some of these descriptors are modified to include contributions 
from neighboring atoms. Using the Top-2 metric, 78% of SOMs were identified, 
outperforming SMARTCyp and StarDrop using either the Top-2 or Top-3 metrics. 
The authors also supply their 394 compound test set in their supporting materials. 
This is annotated with experimental SOM in addition to StarDrop and SMARTCyp 
predicted SOMs. This is an excellent resource for comparison testing of future 
methods. 
Hasegawa et al.65 have developed a machine learning-based approach for the 
prediction of SOMs related to CYP3A4-based metabolism, which combines five 
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quantum chemical descriptors related to reaction energies plus the activation energies 
calculated for the SMARTCyp approach to account for reactivity, solvent accessible 
surface area (SASA) to estimate the exposure of a ligand atom to the heme iron and 
pharmacophoric constraints to reflect the requirements of CYP3A4 for ligand binding. 
The latter were derived from known substrates using MOE.66 Random 
forest/ensemble decision trees were employed to predict metabolic sites with these 
models, with k-nearest neighbor as a baseline method. The model considering only 
reactivity-related descriptors and SASA was outperformed by the models accounting 
for pharmacophoric requirements. The best-performing model included all three types 
of descriptors, with pharmacophoric constraints limited to a distance maximum of 10 
Å, employing the random forest algorithm. Known SOMs were correctly predicted in 
82% of all investigated cases among the two top-ranked atom positions. It should be 
kept in mind that only ten molecules were contained in the test set, which is rather 
small when judging performance of the model in real-world situations, where new 
molecules will almost certainly be outside of the applicability domain. 
A method to predict the metabolic reactivity of small endogenous metabolites has 
recently been presented which combines expert knowledge, computational chemistry 
and machine learning.67 Based on the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway database,68 4843 reactions were characterized and classified into 80 
different reaction classes. SMARTS patterns were used to define chemical 
substructures (reaction centers and surrounding moieties) and the physicochemical 
properties of these were encoded using electrostatic, inductive, energetic, topological, 
steric and distance properties. A SVM binary classification model was trained for 
each reaction center SMARTS pattern in order to predict whether or not a certain 
atom position is a SOM. A score was obtained for candidate reaction centers of a 
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molecule, which was then used to rank the likelihood of a metabolic reaction taking 
place. 3-fold cross validation was performed, obtaining an average sensitivity of 0.74 
and an average specificity of 0.87. Comparable results were found when applying the 
method to predict molecules that have been recently added to the KEGG database and 
which were outside of the training set. Interestingly, the four most important features 
identified were distance properties (encoding the geometrical position of a reaction 
center in a small organic molecule). The encouraging results obtained with this 
approach make it an interesting opportunity to extend its applicability domain to 
xenobiotics. 
Several studies employed protein-ligand docking in combination with other 
approaches to predict metabolism. Lacking a component to account for reactivity, 
docking is frequently combined with quantum chemical methods in order to generate 
a more accurate description of the highly complex catalytic process. In this respect, 
the hydroxylation and O-dealkylation reactions of sirolimus (rapamycin) and 
everolimus (RAD-001) catalyzed by CYP3A4 were analyzed using a combined 
quantum chemical/docking/MD simulations approach.69 The electronic properties of 
both CYP3A4 substrates were described employing B3LYP DFT. The substrates were 
also analyzed by docking on a CYP3A4 homology model using DOCK70 and 
subsequent MD simulations using Assisted Model Building with Energy Refinement 
(AMBER).71, 72 The combined approach turned out to be useful to extend knowledge 
on electronic and orientation effects of substrates of CYP3A4. 
MLite73 is a combined model for CYP3A4-mediated metabolism, employing 
protein-ligand docking and the quantum chemical reactivity estimation method 
developed by Korzekwa et al.74 and Jones et al.,75 see above. Hydrogen atoms 
exposed to the heme iron were identified by docking and reactivity was considered 
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based on the results of quantum chemical calculations. In the case of O-dealkylation, 
a penalty for the activation energy was required to lower the number of incorrect 
predictions by the reactivity-based approach. The optimized model gave 76% correct 
predictions for the 25 compounds of the test set when considering the two highest-
ranked atom positions for each molecule. This approach is related to a further method 
developed by this research consortium,76 which also employed the semi-empirical 
(AM160) method developed by Korzekwa et al. and Jones et al. for reactivity 
estimation - in this case for CYP1A2. AutoDock was used to orientate the ligands in 
the binding site, to examine potential SOM and to estimate binding free energies. The 
overall prediction of SOM was derived from both measures. The SOM of eight out of 
twelve substrates were correctly predicted as the primary SOM and for all of them as 
the secondary SOM. 
Insufficient structural data on the conformational flexibility of CYPs is still limiting 
the applicability of docking approaches for this enzyme family. Homology modeling 
is one approach to address this problem, in order to derive structural models from 
closely related target structures that can serve as a template for model generation. 
Several CYPs, however, exhibit extraordinary levels of flexibility, which is a major 
problem for structure-based approaches in general. Docking algorithms are highly 
susceptible even to marginal conformational changes of the target structure. The 
approach benefits greatly from using collections of target structures crystallized in the 
presence of ligands of distinct shape and binding modes, so-called ensemble-based 
docking.77 Apo structures of a target in general perform less well compared to holo 
structures due to the absence of a ligand inducing conformational shifts in the binding 
site.52 
27 
If the relevant conformational space of a target is not adequately covered by 
experimental structures, representative target conformations from MD simulations 
may boost docking performance, in particular in cases where heterogeneous binders 
induce conformational shifts in the binding region.77 Thanks to its remarkable 
flexibility,78 CYP3A4 is a prime target for ensemble-based docking approaches. A 
recent study employing an ensemble of CYP3A4 structures derived from several MD 
simulations to identify SOMs points out the importance of covering the 
conformational space of the catalytic binding site.79 
Hritz et al.80 found that the binding site of the apo structure of CYP2D6 is too tight 
to facilitate the binding of 80% of 65 investigated substrates of this isoform. By 
employing an ensemble-based approach, however, they were able to successfully 
identify the correct SOM for all of the ligands with at least one of the MD-derived 
target conformations. In this approach, the known substrates were docked to an 
ensemble of 2500 protein conformations of CYP2D6 derived by MD simulations 
from structures with five heterogeneous substrates bound in order to simulate the 
induced fit effect and thermal motion of the enzyme. To speed up future docking runs, 
a binary decision tree was derived that allows identification of the best suitable 
protein conformation for docking specific ligands. In this way, Hritz et al. were able 
to successfully predict the SOM of CYP2D6 substrates for 80% of all cases when 
docking to the single protein conformation selected by the decision tree model. 
Instead of generating an ensemble of protein conformations for subsequent docking, 
MD simulations can also be employed for refinement of docking results. For example, 
Keizers et al.81 found that automated docking of ligands to CYP2D6 structures is not 
accurate enough to reflect the ligand orientations identified in experiments. Using 
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docked poses as a starting point for MD simulations, they found a significant 
improvement in ligand orientation and SOM prediction. 
Moors et al.82 derived an ensemble of 1000 protein conformations based on a X-ray 
structure of CYP2D6 employing tCONCOORD83 (which employs a set of distance 
constraints to explore the conformational space). Carbons or atom groups with one or 
more hydrogen atoms attached were considered potential SOMs. The closest distance 
between these hydrogen atoms and the heme iron was used to identify the likely 
SOMs. The optimum of that distance was determined to be 2.7 Å. Several different 
docking and scoring protocols were explored, obtaining AUC (area under the ROC 
curve) values of up to 0.93 for an independent test set. 
IDSite84 is a combined approach based on the Schrödinger software GLIDE, Protein 
Local Optimization Program (PLOP - implemented to the Schrödinger software suite 
as the Prime85 package) and a reactivity model derived using Jaguar.86 First, the 
ligand is placed into the CYP active site using docking (GLIDE). Then, two distinct 
refinements are carried out using PLOP. This includes both the refinement of protein 
side-chains and the conformation and orientation of the ligand itself. Poses are filtered 
considering their structures and energies and clustering by similarity of the ligand 
conformations is performed. In the last phase, the best poses are collected based on a 
physical score, which considers the intrinsic chemical reactivity (based on a reactivity 
model derived from DFT calculations employing the B3LYP functional with the 6-
31G* basis set) of potential SOM as well as the energy of the ligand poses. Its 
application on CYP2D6 has been reported recently84 and models for other CYP 
isoforms are currently under development. For a test set of 56 CYP2D6 substrates, the 
correct SOM could be recovered for 83% of all cases. When using a training set of 36 
compounds to fit four parameters (rescaling of the PLOP energy with two parameters, 
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fitting radical intrinsic reactivities and score cutoff), 94% of the known SOMs of a 
test set of 20 compounds were successfully identified. Computational power appears 
to be limiting the application of this approach. The authors report a calculation time of 
approximately 450 hours on a single 2.2 GHz AMD Opteron 6174 processor for a 
compound with three rotatable bonds. 
PREDICTING XENOBIOTIC METABOLITES 
The identification of metabolites of small organic molecules contributes to the 
understanding of ADME and pharmacological properties. Experimental identification 
of metabolites is highly demanding in infrastructural resources, expert knowledge and 
time. If enough material is available, NMR allows structure elucidation of 
metabolites. Mass spectrometry (MS) is particularly valuable for the analysis of small 
amounts of material. Most common experiments are liquid chromatography/mass 
spectrometry (LC/MS) or liquid chromatography/tandem mass spectrometry 
(LC/MS/MS), which allows the identification of moieties of a molecule where the 
biotransformation has taken place (even if they do not always allow for the 
identification of SOMs). These experimental methods can decisively benefit from 
computational approaches supporting data analysis to pinpoint the actual SOM. For 
extensive reviews on these experimental approaches the reader is referred to Refs. 57, 
59, 87. 
While numerous computational methods aim to predict SOMs, only a very few 
approaches have been developed so far that allow prediction of the products of 
xenobiotic metabolism. Prediction methods are dominated by expert systems. 
Additionally, a fingerprint-based data mining approach is available and very recently 
30 
an SVM-based technique has been reported, which, however, focuses exclusively on 
endogenous metabolites (see below). 
Expert systems 
A number of expert systems have been developed that aim to predict the sites and 
products of metabolism using dictionaries of biotransformations. These approaches 
are based on knowledge rules, which are typically developed from a reservoir of in 
vivo and in vitro experimental results. They are inherently subjective in their nature as 
they are based on “expert” human knowledge rather than “robust and objective 
computational estimates” - although given the approximations involved in most 
computational methods these can of course be poor substitutes for the real 
experimental conditions. So, expert systems have a strong history in this area and they 
can help bridge the gap between empirical knowledge and hard data. Potential 
metabolites are identified by searching a query molecule for the presence of a target 
fragment and converting this into a product fragment, as defined by a 
biotransformation dictionary. 
The main drawback with this approach is the generation of a combinatorial 
explosion of predictions, as all possible combinations of transformations permitted by 
the dictionary are considered. Therefore a key challenge is to prioritize the results and 
to stop when it is deemed that the molecule has been transformed into a sufficiently 
water soluble state to enable excretion from the body. A further caveat is that most 
expert systems tend to contain combined data and rules for many different 
mammalian species and so are useful as a general indicator of biotransformations in 
the “average” mammal. However, metabolic pathways can be very different even in 
31 
closely related mammalian species, so some expert systems have been developed to 
allow filtering of specific subsets of the data to a specific species. 
Examples of expert systems include MetabolExpert,88 META89, Meteor,90, 
University of Minnesota Pathway Prediction System (UM-PPS),91 Systematic 
Generation of potential Metabolites (SyGMa)92 and TImes MEtabolism Simulator 
(TIMES),93 as described below. They typically include functionality for the user to 
amend or add new rules to tailor the program to their specific needs and typically 
display the results as a tree of metabolites depicting multiple pathways and molecular 
structures. The main differentiating features apart from different data sources and 
knowledge rules include the methodologies used to prioritize predictions and 
terminate the chain of predictions. 
MetabolExpert was one of the pioneering attempts at a metabolic site predictor, 
created in 1985. The knowledge database contains rules, which include substrate and 
metabolite listings but also contain lists of substructures, which inhibit or promote the 
reaction. The system lists all potential metabolites without applying any ranking 
system and predictions are terminated once known phase II metabolites are generated. 
Features of this system include the presentation of the results in a dendrogram 
showing chemical formulae along with hydrophobicity values and the generation of 
first and second order kinetics data. Additional enhancements include modules 
specific to animal and plant metabolism and soil degradation. 
META uses a larger dictionary of biotransformations, each assigned with a priority 
enabling the metabolites to be arranged hierarchically to manage the combinatorial 
explosion problem. A genetic algorithm is used to prioritize the transformations 
dictionary. Additionally, this system uses quantum mechanical descriptors to test a 
proposed metabolite for stability and convert to a stable conformation if necessary. 
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Further metabolic products are only generated after a stable conformation has been 
achieved. Subsets of the metabolic dictionary can be chosen to allow focus on specific 
areas such as mammalian metabolism, aerobic and anaerobic biodegradation. 
Meteor extends the concept of biotransformation rules by using a structure 
representation language to describe atoms and bonds and is able to include descriptors 
such as charge and valency. This enables a more sophisticated description of the 
activating biophore rather than just functional groups. Over-prediction is countered by 
classifying transformations as probable, plausible, equivocal, doubted or improbable 
and the use of relative reasoning rules to prioritize potentially competing reactions. 
Predictions are terminated once an external logP predictor deems that the molecule 
has become sufficiently water soluble to be excreted. The biotransformation 
probabilities fall with decreasing lipophilicity as the ability of a molecule to cross 
membrane boundaries and undergo further biotransformations is reduced. Additional 
features of Meteor include a link to a metabolism database where examples of the 
biotransformation in the literature are reported with the ability to filter on sequence 
length, enzyme and species. The creators of Meteor note that despite the strategies 
described above Meteor still tends to generate a high volume of false positives. The 
results generated should be regarded as potential metabolites requiring further 
analysis, an observation that is generally true of all expert systems. They also make 
the observation that biological factors are interdependent in a nonlinear way rendering 
it a difficult problem to provide fail-safe rules to encompass all metabolic 
transformations. 
UM-PPS uses a classification system similar to Meteor and biotransformations are 
classified as either very likely, likely, neutral, unlikely or very unlikely. Over-
prediction remains a problem and further relative reasoning rules are used to rank and 
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prioritize predictions. The system is specific to microbial catabolic metabolism and 
uses the University of Minnesota Biocatalysis/Biodegradation Database (UM-BBD)91 
as a source to generate the rules. The creators make similar observations to Meteor, 
that definitive prediction rules applied to a wide region of chemical space are hard to 
generate. They note that predictions work best where query molecules show similarity 
to those already in the database and where reaction conditions and concentrations are 
similar to those documented. The system tends to produce a wide range of predictions 
and so is more suited to general environmental metabolism rather than when applied 
to a specific microbial organism.  
Some other systems use statistical analysis to evaluate a set of biotransformation 
rules when applied to a dataset. SyGMa contains rules derived from inspection of the 
Accelrys Metabolite Database with each rule assigned a probability score relating to 
the number of correct predictions when applied to the database. Metabolites are 
assigned the probability score of the rule from which they were formed, allowing 
them to be ranked. This enables a more finely grained view of probabilities than the 
higher-level categorization performed in Meteor and UM-PPS. To allow for greater 
differentiation and specificity in predictions the rules are broken down into subsets 
and applied to specific chemical reaction series. 
TIMES93 utilizes a comprehensive library of biotransformations and employs a 
heuristic algorithm to generate plausible metabolic maps. Reaction rates from 
systematic and toxicity testing are used to generate transformation likelihoods, 
otherwise a combinatorial algorithm is used to translate known metabolic maps taken 
from reference systems into best-fit transformation probabilities. 
Metabolizer 94 is a commercially available metabolism prediction module which 
enumerates all possible metabolites of a given compound and allows a prognosis to be 
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made on metabolic pathways, major metabolites and metabolic stability. Besides 
human metabolism, it supports predictions on various species including rat, bacteria 
and plants. 
Fingerprint-based data mining approaches 
Metaprint2D-React21 is an extension of MetaPrint2D (see “Predicting Sites of 
Metabolism”) that allows prediction of the metabolites that are likely to be formed 
from a transformation. SMARTS patterns are used to classify the transformations 
based on structural changes between substrate and metabolite and occurrence counts 
for each type of transformation are recorded. A separate occurrence ratio is calculated 
for each type of transformation and the structures of predicted metabolites are 
generated through reaction rules using SMIRKS patterns. Predictions can be selected 
from human, dog, rat or all species. 
Combined approaches 
X-ray structures of CYPs indicate that the position and orientation of substrates and 
their metabolites are largely preserved. Consequently, metabolites would be expected 
to match the chemical and geometric constraints of the binding site, which would 
make them distinguishable from decoy molecules for docking algorithms. This is the 
hypothesis in recent work by Tarcsay et al.,95 who used the expert system 
MetabolExpert to generate putative metabolites from known substrates. The docking 
program GLIDE53 was subsequently employed to reduce the false positive rate. 
MetabolExpert was found to produce 74% of the known metabolites using the default 
setup and 82% following an enhanced rule set. Using the best setup for the 
combination of MetabolExpert with docking as a post-processing filter, Tarcsay et al. 
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report that their method is able to identify the correct metabolite among the three 
highest-ranked structures in 69% of all cases. 
Also MetaSite allows the generation of likely metabolites56 for selected CYP 
isoforms (see “Combined approaches” in section “Predicting Sites of Metabolism”). 
THE CYP SUPERFAMILY OF METABOLIZING ENZYMES 
The CYP family of monooxygenase enzymes facilitate phase I metabolism of 
endogenous and xenobiotic chemicals in many organisms and bacteria. CYPs are 
classified into families and subfamilies. Each family is indexed with a digit, a 
subfamily with a letter and an individual gene with a digit. In humans, many CYP 
isoforms exist, with CYP1A2, 2C9, 2D6, 2C19, 3A4 and 2E1 having been identified 
as playing the most significant roles in drug metabolism. 
Structure of CYPs 
CYPs are predominantly composed of α-helices, labeled A to L, commencing from 
the N terminus (Figure 3). Helices F and G form the roof of the embedded active site 
and between the I and L helices, lies the heme B prosthetic group, which is also 
termed iron protoporphyrin IX. This is present in all CYPs and provides the proximal 
ligand to the heme via the sulfur on the cysteine. Protoporphyrin IX and a small group 
of neighboring residues form a heme cradle region, which is highly conserved. 
Helix I has a highly conserved kink above the active site, which may facilitate 
proton transfer. Otyepka et al.96 have described mammalian (families 2 and 3) CYP 
isoforms based upon available crystal structures. An overview of available X-ray 
structures for CYPs is provided in Ref. 97. 
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Generally, the available crystal structures have had two sets of mutations carried 
out to facilitate their crystallization and purification. Helices F', G', F/G loop and the 
N terminus putatively make contact with the membrane region, hence a large 
hydrophobic transmembrane anchor at the N terminus is replaced with a shorter, more 
hydrophilic chain. Secondly, a four to five sequence polyhistidine-tag is inserted at 
the C-terminus. It is generally accepted that such changes do not modify the reactivity 
properties of the enzyme.98 
The active site volume of CYP isoforms varies as a function of isoform. Cruciani et 
al.99 investigated the structural characteristics of the binding sites of various isoforms 
using GRID. They point out the remarkable differences of the active site volumes 
computed using a hydrogen probe. While CYP1A2 shows a site volume of 630 Å3, 
the binding site of the CYP3A4 model extends to 1500 Å3. They also ranked CYP 
isoforms by the prevalence of hydrophilic regions in the binding pockets as CYP2D6 
> 3A4 > 1A2 > 2C19 > 2C9 and highlighted the strong dependency of the hydrophilic 
patterns on protein flexibility. Otyepka et al.96 partitioned the mammalian CYPs into 
three categories, starting with the largest: CYP2C5, 2C8, 2C9, 3A4 > 2B4, 2D6 > 
2A6. 
Various pathways from the interior active site, leading to the solvent exterior have 
been identified. For a comprehensive study making use of the CAVER100 tool and a 
naming scheme of these pathways the reader is referred to Ref. 101. 
Reactivity of CYPs 
Upon arrival at the active site, a substrate will undergo chemical modification 
facilitated by the heme iron's unusual transient electronic state and the protein 
environment. However, there is a set order to this process. CYP functions within a 
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catalytic cycle, with iron undergoing changes in its spin state, oxidation number and 
ligand coordination number as it proceeds around the ordered cycle. For more detail, 
the reader is referred to the review of Shaik et al.102 The currently accepted 
mechanism is as follows. In its first state, the resting state, Fe(III) is in a low spin, 
doublet state and is hexacoordinated, with a water molecule occupying its distal axial 
position. Arrival of a substrate displaces the axial water leading to the formation of a 
pentacoordinate Fe(III) with a sextet state. The change in redox potential associated 
with this displacement allows it to accept an electron from a reductase, nicotinamide 
adenine dinucleotide phosphate (NADPH)-P450, thus forming the third state, Fe(II) 
that has a high spin state. Molecular oxygen is then bound, yielding state four, a 
singlet, oxy-ferrous complex. This singlet complex, readily accepts a second electron 
from the reductase, resulting in the formation of state five, a ferric-peroxo anion. The 
protein environment facilitates the shuttling of a proton to form state six, which is also 
referred to as Compound 0. 
A second proton is accepted, followed by the heterolytic cleavage of the molecular 
oxygen and loss of a water molecule to form state seven, the electrophilic, high 
valence, iron-oxo compound. This is the active species, analogously termed 
Compound I, which then oxygenates the substrate. Next, the product leaves the active 
site and a water molecule returns to the distal axial position, completing the cycle. 
Compound I is a ferryl-porphyrin-pi cation radical and has three unpaired electrons 
(a triradicialoid). Two unpaired electrons are localized on the ferryl group and the 
other is shared between the sulfur on the covalently bonded cysteine and the 
porphyrin. It is similar in all isoforms and due to its electronic structure being a 
function of its protein environment, has earned itself the title of “Chemical 
Chameleon”.103, 104 Recent electron paramagnetic resonance (EPR) studies have 
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managed to provide experimental evidence for the long sought intermediate, 
Compound I.105 
Molecular dynamics simulations on the structure of CYPs 
Classical MD simulations of various CYP isoforms have been used to gain insight 
into the proteins' flexibility, investigate channels into the active site and generate 
ensembles of structures for higher level QM and QM/MM calculations. This first 
section focuses primarily on classical simulations used to specifically study properties 
arising from system dynamics. Simulations employed as a preamble to generating 
starting QM/MM structures will be covered in the subsequent section. 
Classical parameters developed for CYPs 
Most modern classic biological force fields have parameters for residues and base-
pairs found in proteins and DNA, hence modeling a similar system can be easily 
accomplished. Entities that lie outside of this chemical space, such as small organic 
molecules or unusual residues need special attention and additional preprocessing to 
develop missing parameters. Usually, there is a force field specific protocol for 
parameter development to ensure that the new parameters are consistent with the rest 
of the existing force field. Generally, parameter development focuses on bonded and 
electrostatic terms. A corollary to this is that a parameterization for a moiety within a 
specific force field is not transferable to a different force field. 
The heme B prosthetic found in CYPs is such a group and various parameters for 
different force fields have been developed over time. A further complication to this 
arises due to iron's changing electronic state as it proceeds around the CYP catalytic 
cycle, since each state will have different classical parameters.102 A range of 
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parameterizations for the heme B prosthetic in CYPs have been carried out, some 
exclusively as a parameterization process, others for use within a specific study 
(Table 2). 
In their study of the interaction of the P450cam isoform with valproic acid, Collins 
et al.106 developed a set of heme B parameters for use with AMBER 3a. Schöneboom 
et al.103 derived Chemistry at HARvard Molecular Mechanics (CHARMM)107, 108 
parameters for Compound I based on existing CHARMM heme parameters, by 
adding axial ligands and updating charge parameters. Bathelt et al.109 carried out a 
similar process with the CHARMM22 parameter set. Oda et al.110 developed AMBER 
parameters for the pentacoordinate Fe(III) in the sextet state, and Seifert et al.111 
reported AMBER parameters for CYP in the Compound I state. Favila et al.112 
presented improved heme B parameters to carry out MD simulations on CYP2C9 and 
CYP19 (also known as aromatase).  
Although not CYP parameters, the classical force field parameters for the heme C 
prosthetic developed by Authenrith et al.113 for both the CHARMM and AMBER 
force fields provided a foundation for derived CYP parameters by Skopalík et al.114 
(resting state) and Favia et al.112 (ferrous low spin state). 
Shahrokh et al.115 have recently developed a set of AMBER compatible CYP 
parameters, which are readily accessible in their supporting information, for a range 
of heme states found in its catalytic cycle. 
Classical simulations of CYPs 
The majority of simulations to date have been carried out with either the AMBER 
or CHARMM force field, although some have also utilized variants of the GROMOS 
or OPLS force field. All simulations have made use of explicit water solvent and 
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followed a standard MD protocol. Recent simulations are on average 20 ns long, and 
in a few cases are an order of magnitude greater than this. However, since simulation 
length is largely dictated by available computational power, older simulations are 
shorter. Generally, the simulations described here make use of a standard protocol for 
condensed phase biological MD as outlined below. 
A crystal structure usually provides starting coordinates, but if there are missing 
residues or if a crystal structure is unavailable, homology modeling methods may be 
used. Missing hydrogens are then added. The correct protonation state of certain 
residues at physiological pH is assigned according to estimation of local pKa, before 
finally assigning force field terms to the system. Counter-ions are added to neutralize 
charge in the system and to provide a solvent salt concentration that reproduces 
physiological or experimental conditions as appropriate. The system is placed under 
periodic boundary conditions and Particle Mesh Ewald (PME) is used for accurate 
treatment of long-range electrostatic interactions. Next, energy minimization is 
carried out to relax any bad contacts between protein and solvent, followed by short 
thermalization (allowing the system to reach the desired temperature) and 
equilibration MD phases, prior to the production simulation. In some cases, extra 
biasing potentials or force field modifications may be introduced, for example, to 
calculate the thermodynamics of CYP binding site solvation and ligand binding, or to 
delineate substrate access pathways. 
During normal production dynamics, the backbone RMSD relative to the original 
experimental or modeled structure may be monitored over time to check that the 
protein is stable under the influence of the simulation force field. Analysis approaches 
may include the calculation of the per-residue root mean squared fluctuation (RMSF), 
which provides a measure of backbone mobility and can be directly compared to 
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crystallographically-derived temperature-factors. Large concerted motions may be 
identified using principal component analysis (PCA; the result of diagonalization of a 
covariance matrix that has been calculated from the dynamics), which filters out rapid 
thermal atomic fluctuations. Finally, the molecular details and energetic interactions 
between protein, ligand, and solvent may be analyzed, supplemented by visual 
analysis of the trajectory. 
Early simulation studies focused on the local structure/dynamic relationships 
associated with alternative ligand binding modes in CYP isoforms. Wade and et al. 
designed a series of camphor analogues designed to fill an empty region of the 
substrate binding pocket of P450cam and a mutant, and experimentally measured 
thermodynamic properties of binding were rationalized via substrate-protein/solvent 
interactions observed in MD simulations.116 The same group applied multicopy MD 
simulations, in which several ligands are simulated in the presence of a single protein 
to locally enhance sampling, to explore multiple ligand binding modes of different 
enantiomers of camphor in P450cam, revealing differences in binding modes for 
similar but chemically different ligands.117 The structural reorganization associated 
with differential substrate selectivity in CYP17 isoforms from various species has also 
been investigated via MD simulation approaches.118 Moreover, simulations of a 
CYP2A4 model has helped to rationalize key interactions with active site residues 
shown via mutation to determine specificity for testosterone metabolism (in contrast 
with CYP2A5).119 Strobel et al.120 used simulations to provide a molecular 
explanation for the observation that inactivators are able to discriminate between the 
closely related CYP P450 isoforms 2B4 and 2B5 in terms of differential stabilities of 
inhibitor binding orientation. 
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Several simulation studies have sought to provide a molecular basis for the 
promiscuous nature of substrate specificity exhibited by CYPs in terms of their 
dynamics. Park et al.121 used nanosecond-timescale MD simulations of CYP3A4 to 
propose that the high-amplitude flexibility of a loop near to an egress channel in the 
apo state (but damped when bound to a substrate or inhibitor) may be responsible for 
the enzyme’s broad specificity. More recently, Lampe et al.122 generated 200 ns 
trajectories of the thermophilic P450 CYP119 enzyme, providing evidence for a 
flexible conformational selection mechanism in substrate binding, and revealing from 
an analysis of correlated motions that the active site moves relatively independently 
from the rest of the protein, leading to “insulation” from external dynamics.123 Seifert 
et al.111 examined the interaction of CYP2C9 with its substrate, warfarin, using an 
AMBER FF99 model with their own heme B parameters. Multiple 5 ns trajectories 
were run and they observed a stable protein core and a mobile surface that gave rise to 
two channels, and concluded that this leads to a broad substrate profile with high 
regioselectivity. Sano et al.124 studied three polymorphisms of CYP2C9 which 
involved the mutation of a single amino acid residue, using MD and docking methods, 
and related catalytic activity to deformations of this pocket. 
Skopalík et al.114 carried out simulations on three members of CYP3A4, 2C9 and 
2A6. In addition to the standard MD simulations of each isoform, a MD run was 
carried out at 398 K. High temperature simulations enable a more extensive sampling 
of protein dynamics, and have previously been used, for example, to understand the 
origins of stability of the thermophilic and barophilic CYP119 enzyme via 
nanosecond-timescale simulations.125 An analysis of the dynamics of the three 
isoforms revealed that CYP malleability is directly related to substrate specificity. 
CYP2A6 was the most rigid investigated CYP and consequently has a narrow range 
43 
of substrates, while CYP3A4 was the most flexible and most promiscuous analyzed 
CYP. They also identified ten flexible regions and a rigid core as well as a malleable 
distal side and a less flexible proximal side. Such observations could not be concluded 
from previous X-ray structure analyses, as a comparison of calculated and 
experimental B-factors confirmed that protein dynamics are damped in the presence 
of crystal lattice contacts.  
CYP substrate specificity and associated conformational flexibility has also been 
investigated via combined simulation and experimental approaches. A flexible loop 
around the active site has been observed in a CYP2C9 mutant, leading to a more open 
conformation consistent with spectroscopic data.126 In another study, NMR-derived 
residual dipolar couplings were incorporated via torsional restraints within MD 
simulations of P450cam to identify a more open and accessible active site with a 
wider range of substrate orientations than those observed crystallographically.127 
Sigmoidal behavior in kinetic studies led Fishelovitch et al.128 to examine the 
possibility of cooperative binding between two substrates. They modeled diazepam in 
CYP3A4, comparing simulations of this with the substrate-free state, and concluded 
that F304 on the proximal I helix plays a key role in the mechanism of co-operativity 
between substrate molecules. 
Significant effort has been devoted to understanding the properties of internal CYP 
solvation. While the volumes of the active sites of different CYPs vary significantly, 
they have been shown to contain water that must be displaced upon substrate binding, 
and this must be considered when attempting to calculate the binding free energy of a 
particular substrate. Moreover, the reactivity of the active site is dependent upon 
water. Displacement of water favors the ferrous Fe(II) state and prevents electron 
uncoupling,129 whilst water “wires” may relay proton transfers needed for heterolytic 
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cleavage of dioxygen. Only limited information regarding water occupancy may be 
extracted from crystal structures, necessitating complementary simulation approaches. 
Several factors contribute to this issue, such as conformational flexibility of the 
protein, the difficulty of cryoprotection schemes as well as the disordered nature of 
solvent molecules. 
The simulations of Skopalík et al.114 enabled observation of water exchange 
between the active site and bulk solvent, with the number of water molecules reaching 
a dynamic equilibrium after 1.5 ns. Analysis of access/egress channels (pw2e and 
pw2c) identified a solvent channel. In a more recent analysis, Hendrychová et al.130 
examined the effect of high pressures (300 MPa) upon CYP1A2, 2A6, 2C9, 2D6 and 
3A4 both by experimental spectroscopy and molecular dynamics simulation. Using a 
similar protocol as in their previous paper, they found that with increased pressure, 
the flexibility of the CYPs decreased and the number of water molecules in the active 
site increased, with the exception of CYP3A4. They also concluded that of the five 
CYPs examined, CYP2A6 and 1A2 have the least malleable active sites. 
Because of the relatively long timescales required to observe water exchange 
between internal cavities and bulk solvent, Helms and Wade131 implemented a 
pioneering “alchemical” MD approach, in which a water molecule is gradually 
annihilated in bulk solvent and another is inserted into the protein cavity, enabling 
calculation of the relative free energy of hydration of the CYPcam active site via a 
simple thermodynamic cycle. This revealed that hydration by around six water 
molecules was thermodynamically most favorable, in agreement with experimental 
estimates, suggesting the active site water density is about half that of bulk solvent. 
Recent improvements in computational power enabled Miao and Baudry132 to observe 
the unbiased water diffusion into and out of the active of P450cam over a 300 ns 
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trajectory, confirming that on average, six water molecules are found in the camphor-
free active site. However, between zero and twelve water molecules could be present 
at any given time, since solvent exchanged rapidly with bulk solvent via multiple 
channels identified with the CAVER100 tool. Rydberg et al.133 also showed that active-
site waters could exchange with bulk during 4 ns simulations of six mammalian 
CYPs. The mean number of waters and exchange pathways varied significantly 
between isoforms, consistent with the variability in active site volume.99 
MD simulations have also been utilized to study the effect of organic co-solvent 
molecules such as DMSO on the structure and dynamics of CYPs134, 135 for 
commercial exploitation, since many industrially important substrates are poorly 
soluble in water. Moreover, a series of 1 ns MD trajectories have been used to identify 
docking sites for CO binding to P450cam, rationalizing laser flash photolysis data.136 
Because the active sites of the CYP, enzymes are substantially buried within the 
protein structure, specificity and kinetics are likely to be directly linked to the passage 
of water, substrates and products into and out of the protein. For this reason, much 
focus has been placed on the identification of static or dynamic channels that connect 
the active site to the protein surface. Available crystal structures yield a wealth of 
information regarding access/egress channels101, but simulation approaches can 
complement this by providing insight into the dynamics and energetics of substrate 
passage. For example, Fishelovitch et al.137 identified a gated water pathway and an 
additional substrate channel in CYP3A4 using their MolAxis tool.138 A second 
MolAxis channel study on the same isoform139 examined cooperative binding of 
ketoconazole and ligand-induced conformations changes. The authors also identified 
various bottleneck residues, and concluded that two channels could serve as egress 
routes for the substrate ketoconazole. Haider et al.140 identified three channels that 
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converged on the heme in a homology model of CYPC17, identified using the MOLE 
tool.141 MD simulations demonstrated different substrate binding modes, and a 
correlation between low vibrational modes and active site gating was demonstrated. 
Accelerated MD approaches have also been developed to lower the energy barriers 
between different crystallographically-identified open and closed conformational 
states of P450cam, providing insight into the likely mechanisms of ligand binding.142 
The direct observation of ligand/product entry/exit is generally not possible using 
typical MD simulations due to limitations in accessible timescales. As a result, a 
variety of “biased” simulation approaches have been utilized to enhance sampling of 
ligand egress within CYPs.143 The Wade group developed the random expulsion MD 
method, involving the application of a randomly oriented artificial force to an 
initially-bound ligand, to identify channels in three bacterial CYPs.144 Steered MD, in 
which a constant force is applied to a virtual spring attached to a molecule along a 
pre-defined vector, was subsequently used to drag ligands along each channel. A 
minimization-based approach identified a channel common to all three bacterial CYPs 
- with specific channel features in each isoform adapted for their respective 
substrate/product specificity - as the most likely route of ligand passage.145 A similar 
approach was applied to a mammalian CYP2C5 enzyme, and used to propose that 
hydrophilic substrates and products may pass through one channel, whereas lipophilic 
substrates may enter via a channel embedded within the membrane.146 This was 
recently supported by the first reported MD simulations of a full-length mammalian 
CYP inserted within a lipid bilayer.147 Coarse grained simulations were used to 
efficiently sample various orientations of the membrane-bound CYP, providing the 
starting point for subsequent all-atom simulations. Correlations were found in the 
permittivity of putative ingress and egress tunnels, and presence of the membrane 
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stabilized the open state of an internal aromatic gate in the previously identified 
channel connecting the active site to the bilayer phase. 
The steered MD method and its variants have been applied to a number of other 
CYP systems including CYP2B1148, 149 and CYP3A4,150-152 enabling the identification 
of possible channels and associated rupture forces during ligand passage, and to probe 
interactions with key residues identified by site-directed mutagenesis. As it becomes 
easier to generate longer timescales and steered MD simulation ensembles, it has even 
become possible to estimate the free energy pathways associated with ligand entry 
and egress.153 
Molecular dynamics approaches for the calculation of affinity of substrates 
and metabolites 
As well as providing qualitative information concerning protein-ligand interactions, 
a number of methods within the MD simulation framework may be utilized to directly 
estimate ligand binding energies. Although this tends to involve greater computational 
cost than e.g. docking, the results are normally more reliable due to the use of an 
accurate physical force field and extensive conformational sampling (if sufficient 
starting points are included). In more or less all the approaches, calculation of the 
ligand binding free energy (∆G) relies on the observation that its value is a state 
function and is hence dependent only on its initial energy in solution and final energy 
following binding. Thus, a thermodynamic cycle may effectively be invoked, 
considering either the “transfer” of a ligand into solution and into the protein binding 
site, yielding the absolute binding energy, or the transfer of two different ligands to 
the binding site, yielding the relative binding energy. 
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For example, Åqvist et al.154 devised the semi-empirical linear interaction energy 
(LIE) technique to estimate ligand-protein binding energies. In contrast with some 
more rigorous approaches (see below), only the physically relevant protein-bound and 
free solvated states of the ligand (i.e. the “corners” of the thermodynamic cycle) are 
considered with LIE, necessitating just two MD or Monte Carlo simulations.155 From 
the equilibrium ensemble of non-bonded interaction energies between the ligand and 
its surroundings for these two states, ∆G may be calculated as an empirically 
weighted difference between the average bound and unbound energies. There are 
separate scaling coefficients for the non-polar and electrostatic interactions and an 
extra independent constant may be included. Whilst default values for these 
parameters are available, they are often optimized using a training set. Good 
correlation between experimental and calculated binding energies has been 
demonstrated in many cases when utilizing LIE, particularly for related series of 
ligands, and as early as 1996, it was shown that the approach could be successfully 
applied to the estimation of relative and absolute binding free energies for a range of 
substrates in P450cam.156 
Vasanthanathan et al.157 investigated ligand binding affinity of thirteen ligands with 
CYP1A2 using a LIE-based method. GOLD was initially used to place the ligand in 
the active site, followed by a standard MD protocol using the GROMOS 45A4 force 
field, totaling 1 ns of NPT production dynamics. From this trajectory ∆G was 
calculated using LIE. For comparison and validation, experimental IC50 values were 
converted to equilibrium constants (Ki), which in turn were used to estimate ∆G. They 
demonstrated a linear correlation between experimental and calculated values with a 
RMSD of 2.1 kJ/mol, and concluded that the van der Waals interaction dominated 
over the electrostatic. 
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Karlsson et al.158 constructed homology models of 26A1 and 26B1, and various 
ligands, including five retinoic acid metabolizing blocking agents (RAMBAs), were 
docked into each respective site, followed by 0.5 ns of NVT MD simulation. The LIE 
method was used to calculate values of ∆G which were compared to experimental 
IC50 values. The authors concluded that the homology models could distinguish 
between strong and weak inhibitors and identified various important residues in the 
active site. 
Stjernschantz et al.159 developed an iterative protocol employing multiple MD 
simulations accounting for an ensemble of generated docking poses. The approach 
was tested on a set of twelve known binders of CYP2C9 and the RMSD for predicted 
binding affinity was 2.9 kJ/mol. It was shown that this technique is able to lower the 
impact of the initial pose selection and it also takes into account the possibility of 
multiple binding modes. 
Despite these reports, which often demonstrated impressive correlation between 
experimental and calculated ∆G, the inherently empirical nature of LIE may be 
undesirable in some cases. An alternative is to use “computational alchemy”, which 
includes related methods such as free energy perturbation (FEP) and thermodynamic 
integration (TI). Such formally correct approaches tend to be computationally 
demanding, but have the capacity to yield highly accurate relative or absolute ligand 
binding free energies, in principle limited only by the quality of the underlying force 
field and sufficient conformational sampling.160 
The key feature of alchemical methods is that the configurations sampled between 
different states should have a significant degree of “overlap”.161 Thus, unlike in LIE 
where two ensembles must be generated, a multistep approach must be used, in which 
a path between the “corners” of the thermodynamic cycle (see above) is sampled. 
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Practically, this is normally implemented by introducing a series of intermediate 
potential energy functions constructed as a linear combination of end states. Thus, one 
ligand is alchemically transformed to another (to yield the relative ∆G), or a ligand is 
alchemically “annihilated” (for the absolute ∆G). 
Wade et al.131 utilized an alchemical MD approach to calculate the relative ∆G of 
water molecule binding to the CYPcam active site, and later extended this work to 
couple the exchange of six high-occupancy water molecules to the alchemical 
transformation of camphor inside the active site, yielding an accurate measure of its 
ligand binding ∆G.162 Deng and Roux161 pointed out that this strategy required prior 
knowledge of the solvation properties of the cavity in question. They therefore 
recently implemented a novel approach combining alchemical MD for ligand-binding 
∆G calculation, with a grand canonical Monte Carlo algorithm, enabling the number 
of waters to vary freely during the simulation. This yielded extremely accurate 
estimations for the thermodynamics of camphor binding to P450cam,163 and the 
method should be generalizable to any CYP site. It is clear that careful consideration 
of CYP solvation properties is necessary, even when combining MD with more 
empirical approaches to binding ∆G calculations.157 
QM/MM approaches with CYPs 
Classical simulations can yield information about dynamics and conformation 
changes. However, this level of theory does not have the ability to represent bond 
breaking or making processes, whereas a richer quantum mechanical treatment of all 
the electrons within the system, is still too computationally demanding. 
A common approach is to partition the calculation into two regions which are 
treated at different levels of theory. Generally, a small quantum mechanical region is 
51 
defined around the active site, where bond breaking is presumed to occur, and the rest 
of the system, usually the rest of the protein and bulk solvent, is treated classically. 
The two regions are not independent, but are coupled. For example, the wavefunction 
in the QM region will be polarized by the influence of the point charges in the 
classical MM region, and conversely, the MM region will be influenced by a non 
static point charge distribution emanating from the QM region. Many coupling 
methods exist and the QM/MM approach can be used to calculate single point 
potential energies or gradients can be evaluated for the system to be propagated 
dynamically (QM/MM MD). 
The Thiel group has published several excellent papers characterizing the dynamics 
and catalytic mechanism of CYPs. Their work includes investigations on polarization 
and hydrogen bonding effects of the protein environment on Compound I.103 They 
carried out 215 ps of MD using their protoporphyrin IX parameters to generate 
snapshots for subsequent QM/MM calculations and concluded that it transformed 
from a sulfur-centered radical to a porphyrin-centered radical cation. Further studies 
from this group include the QM/MM-based analysis of the C-H hydroxylation 
mechanism164 and the theoretical investigation of the Compound I reactive 
intermediate.165 This and additional work is discussed in their comprehensive 
review102 on the structural properties, reactivity and substrate selectivity of CYPs 
analyzed by QM/MM approaches and therefore we provide here a brief summary on 
this topic. 
Starting configurations are usually generated from a classical MD simulation. A 
QM/MM hybrid approach is used whereby a truncated porphyrin (both propionate 
groups are removed) and a truncated cysteine (S), is set as the QM region. In the QM 
region, an UB3LYP method is used with the Los Alamos effective core potential and 
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associated triple zeta contracted basis, LACVP, on Fe and the 6-31G(d) basis on the 
remaining QM atoms.166 
Bathelt et al.109 examined the electronic properties of Compound I and concluded 
the lowest electronic state to be a near degenerate pair of doublet/quartet 
optimizations of A2u states, with two unpaired electrons localized on the Fe-O and 
the other delocalized on the porphyrin and thiolate ligand. In a later study,167 they 
examined the mechanism of benzene hydroxylation facilitated by CYP2C9 and found 
that the energy barrier for the addition step is comparable to the experimental rate 
constants of the same family member, CYP2E1. They also compared the energetics of 
benzene approach towards the side or face (relative to the porphyrin plane) and 
concluded that these arene addition pathways are both accessible. 
Fishelovitch et al.168 explored the effect of a substrate on Compound I, showing that 
in a substrate-less Compound I state, the Fe-S bond elongated and localized the 
radical on the sulfur. Conversely, the presence of substrate shortened this bond. 
Sen et al.169 studied the dynamics of CYP51 with specific reference to the proton 
shuttling involved in the molecular oxygen activation. They conclude that the protein 
environment is important in tuning the electronic structure of intermediates and 
highlighted the range of proton shuttling routes within the CYP family. The study also 
demonstrates opportunities for experimental validation since much experimental data 
is available for the peroxo intermediate. 
Lonsdale et al.170 investigated the chemoselectivity of alkene oxidation with 
CYP101, finding that QM/MM reaction barrier heights were in qualitative agreement 
with experimental selectivities. Given the accessibility of both hydroxylation and 
epoxidation to the ferryl oxygen, this is the relative reactivity of Compound I which 
determines the relative ratio of products. Attention is also drawn to the complexities 
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of such modeling and the need for a wide ensemble of starting geometries for 
QM/MM approaches. In a different study,171 the same author demonstrates the 
importance of a dispersion correction for B3LYP methods in the study of CYPs. Their 
work showed that inclusion of dispersion has a significant effect on the energies and 
geometries of transition states and encounter complexes. Furthermore, an improved 
agreement with experimental data was observed compared to their original CYP101 
study.170 
Li et al.172 conducted a QM/MM study of CYP2A6 on (S)-(-)-nicotine. From 
calculating a minimum QM/MM energy path they determined a reaction method: 
initial abstraction from the 5'-position to the oxygen on Compound I followed by an 
O-rebound step, the recombination of the nicotine moiety with the iron hydroxyl to 
produce the 5'hydroxynicotine product. They conclude that nicotine exists in a less 
favorable protonation state when undergoing CYP catalysis. 
The reaction mechanism of the conversion of tyramine to dopamine, as catalyzed 
by CYP2D6 was examined by Schyman et al.173 The traditional Meisenheimer-
complex mechanism, i.e. direct aromatic hydroxylation, was ruled out based on 
energetics. Instead, they deduced that the reaction path is entirely dictated by the local 
electric field of the protein environment. An initial phenolic H-abstraction of the 
protonated tyramine by Compound I is followed by a phenoxyl ring rebound, 
culminating in a keto-enol rearrangement to dopamine, outside of the protein. 
Interestingly in this QM/MM study, the authors found that only a 3 Å radius sphere of 
the charges from the MM environment needed to be included in the QM/MM model 
for the H-abstraction intermediate to be stabilized to a value comparable to that of the 
full QM/MM model. 
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The mechanism of H-abstraction, followed by O-rebound is common between these 
two simulations. However, the tyramine is in a protonated state (protonated amino 
tail), whereas nicotine is in its unfavorable free base state. 
A more recent study by Lonsdale et al.174 investigated the electronic structure of the 
Compound I state between different CYP isoforms using a QM/MM approach, with 
the Compound I Fe-O bond enthalpy as the comparison metric. Interestingly, they 
find that there is little variation between the three isoforms they examined, and 
significantly more variation within a single isoform's ensemble of MD generated 
structures. They conclude that the hydrogen bonding, the polarizing environment and 
thermal fluctuations influence Compound I's electronic structure and stress the 
importance of using an ensemble of structures in QM/MM studies. They also state 
that the substrate's presence in the cavity alters the electronic structure of Compound 
I. It reduces the number of hydrogen bonds that ferryl oxygen has to the water 
solvent, increasing the spin density on ferryl oxygen, thus weakening the Fe-O bond. 
Predicting interaction of xenobiotics with CYPs 
Interaction of xenobiotics with metabolizing enzymes is likely to lead to substantial 
changes in biological effects, potentially causing a loss of activity or toxic effects. 
CYPs are key metabolizing enzymes, accounting for approximately 75% of total 
metabolism.175 They play a pivotal role in drug metabolism, where seven of the 57 
known human CYP isoforms facilitate more than 90% of the metabolism, as well as 
DDIs.176 Polymorphism of certain CYP isoforms such as CYP1A2, 2D6, 2C9 or 2C19 
add another layer of complexity to the problem.177-179 Due to the wide range of 
metabolism rates observed for xenobiotics, determination of the kinetic profile and 
optimization of dosing (to remain within the therapeutic window) becomes an even 
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more challenging and sometimes impossible task. Mutations of metabolizing enzymes 
and their impact on the kinetics of drug molecules are difficult to predict and would 
require a substantial computational effort for each compound and CYP. 
Consequently, prevention of interaction of compounds with polymorphic CYPs by 
rational design is a favorable strategy. 
Predicting DDIs is a non-trivial and complex problem that has been traditionally 
addressed in elaborate clinical studies.180 Even for the extrapolation of in vitro assay 
data to in vivo effects some major uncertainties and controversies exist.181 Several in 
vitro CYP inhibitors, such as clotrimazole and other compounds sharing an imidazole 
scaffold, have been observed to induce these proteins in vivo.182 One major challenge 
in predicting systemic effects derives from the crosstalk of receptors regulating 
metabolizing enzymes.183 Though in vitro assays are becoming more readily available 
and more and more insight on the mechanism of inhibition and induction of metabolic 
enzymes has been gathered, a complete framework that would allow the accurate 
prediction of enzyme inhibition and induction is still missing.5 Here, we provide an 
overview of computational methods aimed at (among other functions) the prediction 
of interactions between xenobiotics and CYPs. For more detail, the reader is referred 
to Refs. 7, 184, 185. 
Predicting CYP inhibition by xenobiotics 
CYP inhibition is in general considered to be more problematic than CYP 
induction. CYP inhibition may cause toxic effects by an increase of activity at targets 
and anti-targets and is commonly evaluated by determining the inhibition constant, Ki, 
using liver microsomes or cDNA-expressed microsomes.179 CYP induction is a 
central focus for drug safety, potentially leading to a loss of therapeutic efficacy due 
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to increased metabolism rates but also to an increased production of toxic metabolites 
(see below). 
QSAR and machine learning methods. 
MD simulations are typically able to deal with previously unseen ligand-target pairs 
when attempting to predict metabolic sites on small molecules or their binding 
affinity (see “Molecular dynamics simulations on the structure of CYPs”). However, 
they are at the same time computationally demanding and, consequently, they are not 
always applicable, particularly when time is at a premium. In real-world situations, 
very often an interactive, “immediate” prediction of the likelihood of being a substrate 
or an inhibitor of particular CYPs is desired, for instance when medicinal chemists are 
interactively designing a series of structures. QSAR, machine learning and other 
approaches are in many cases well suited to provide this kind of instant feedback to 
the user. At the same time, they are both based on prior knowledge. Hence, their main 
shortcoming is, generally speaking, their limited extrapolation ability to novel 
chemical series or molecules outside of their applicability domain. 
QSARs attempt to derive quantitative relationships between the structure of a 
compound and its activity. Those relationships are based on the principle that the 
chemical structure of compounds -and similarities and trends of a chemical series- are 
related to the molecular properties exhibited.186 Hence, in order to generate 
relationships between structure and function, a way to describe the molecule is needed 
(see Ref. 187 for a recent review), as well as a suitable statistical or machine learning 
method188 to generate the particular SAR of interest. Activity in the particular context 
of this review means the inhibition of one or more metabolizing enzymes, in 
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particular isoforms of the P450 enzymes by a small molecule, or its ability to act as a 
substrate of these enzymes. 
What is remarkable about the area of QSAR in toxicology and metabolism is that 
guidelines for the validation of models have only relatively recently been published, 
as part of the Organisation for Economic Co-operation and Development (OECD) and 
European Union efforts to reduce the amount of animal testing performed in the 
context of exploring properties of novel chemical entities (NCEs). In order to trust 
QSAR models – which are essentially computational predictions of molecular 
properties - without resorting to experiment in every single case, requires validation 
and tests of robustness, and is fundamental in order to gain trust in the models. In this 
context, it might be useful to consider a recently published summary of requirements 
pertaining to a practically useful QSAR model as follows (according to OECD 
guidelines): “The guidelines recommend that QSAR models should be associated 
with (i) a defined end point, (ii) an unambiguous algorithm, (iii) a defined domain of 
applicability, (iv) appropriate measures of goodness-of-fit, robustness, and 
predictivity, and (v) a mechanistic interpretation, if possible”.189, 190 Certainly, these 
are essential criteria that should be applied to any trustworthy QSAR model upon 
which important practical decisions will be based. 
The term “QSAR” does not immediately define which mathematical methods are 
used to derive those SARs. They can be statistical models, or more complex machine 
learning models such as SVMs,191 random forests192 and similar approaches. In the 
following we will discuss approaches to predict CYP inhibitors and substrates using 
conventional (statistical) structure-activity modeling methods as well as machine 
learning methods applied to the area. Apart from reviewing work directly, the reader 
is also referred to previous reviews for further information, namely those focusing on 
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QSAR modeling applied to CYP metabolism178, 184, 185, 193, 194 as well as those focusing 
on the machine learning approaches to the field.178, 195-198 What is also remarkable is 
that in the field of metabolism or ADME/Tox prediction in general, “open” (free, and 
often open-source) approaches are making progress, in tandem with public bioactivity 
databases199 etc. The reader is referred to a recent review of the field for an overview 
of many of the current available tools.200 
Approaches to classify or quantify the interaction of chemical compounds with 
members of the CYP family can also be differentiated depending on how data is 
analyzed. Models can be generated for either inhibitors, substrates, or, most generally 
“ligands” or interaction partners of the enzyme. They can be either global or local, 
depending on the size and nature of the dataset. While global models are built on 
large and diverse collections of compounds and therefore have a large domain of 
applicability, local models are specialized to a very specific chemical and biological 
space. Global models generally maintain their performance when predicting more 
diverse molecules (and properties), while local models may show superior prediction 
accuracy within the chemical space they are trained on. 
Models can be either trained on molecules with measured activities for a whole 
enzyme family or for a specific isoform. Most challenging for the development of 
models is the fact that biological data such as IC50, Ki and Km values depend very 
much on the experimental conditions (these are indeed different experimental 
measures which are often, through the sparsity of data, combined in single models), 
which leads to a significant variance in the data. Good models may thus be able to 
explain 65% to 85% of the variance in a dataset. Models reported with higher 
accuracy are very likely to be overfitted. 
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Furthermore, different parameters can vary from model to model, such as the 
composition of the training set, the validation method, the choice of descriptors, and 
last but not least, the mathematical modeling method employed to generate SARs. 
Here again, models may be based on categorical or continuous variables. All of the 
above factors generally differ between models to be compared, and this needs to be 
kept in mind when relating the performance of models to each another. For more 
information on modeling toxicity data and its challenges the reader is referred to a 
recent review.201 
Classification models 
As an example of a relatively typical classification study, k-nearest neighbor, 
decision trees, random forests, ANNs and SVMs using different kernels were 
employed to predict substrates, inhibitors or “interactors” with the CYP1A2, 2D6 and 
3A4 isoforms based on a set of 335 structurally diverse compounds.202 188 descriptors 
such as atom counts, charge properties and connectivity indices were used for model 
building, employing 10-fold cross validation as a model validation method. 
Classification performances of 81.7% to 91.9% for CYP1A2, 89.2% to 92.9% for 
CYP2D6, and 87.4% to 89.9% for CYP3A4 were obtained. Interestingly, in this work 
various decision tree methods were found to outperform “numerical” methods such as 
SVMs – a result that seems not to hold when applying these algorithms to larger 
datasets.203 
While single metabolizing enzyme predictions are easier to perform from the 
computational side, they do not reflect the situation that in reality many compounds 
are metabolized by more than one enzyme. To reflect this situation, in a more recent 
study204 a total of 580 CYP substrates of seven different isoforms have been analyzed 
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by applying multi- and single-label classification strategies, including SVMs, multi-
label k-nearest neighbor classifiers, as well as ANN modeling methods. While single-
label and multi-label classifiers at first sight seem to achieve similar performance, the 
authors state that “the multi-label approach more coherently reflects the real 
metabolism information”, namely that compounds are in many cases metabolized by 
different CYP isoforms, though at different rates and giving rise to different 
metabolites. In this particular case, out of the 580 compounds 488 were metabolized 
by a single CYP isoform, while the remaining 92 structures are metabolized by up to 
five enzyme variants. 
The idea of having “true negatives” in a dataset is also critical to address. However, 
compounds of unknown activity are often treated as “putative inactives”. This was 
however approached explicitly in a recent study where for CYP3A4, 2D6, and 2C9 
inhibitors and substrates were analyzed using SVMs.205 For the prediction of 
inhibitors, only CYP3A4 and 2D6 were used, but substrate models have been 
generated for all isoforms. In particular, two consensus SVM methods, namely 
"positive majority" and "positive probability" were employed in this work on a large 
dataset comprising several hundred active datapoints. In addition to the inhibitors and 
substrates, likely “non-inhibitors” and “non-substrates” were generated. The model 
obtained accuracies for classification of substrates and non-substrates, respectively, of 
98.2% and 90.9% for CYP3A4, 96.6% and 94.4% for CYP2D6, and 85.7% and 
98.8% for CYP2C9. Regarding the different machine learning methods employed, the 
consensus support vector machine methods were generally found to give better 
performance than those based on single SVM classification systems. 
In many cases, datasets are not balanced, which poses additional challenges when 
developing machine learning models. In a recent study using CYP2D6 inhibitors,206 a 
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set of 185 training and 78 test datapoints were employed using “ensemble” 
descriptors (containing atom counts, constitutional descriptors, topological descriptors 
etc.) in combination with a SVM. In this work, the influence of various oversampling 
and “threshold moving” techniques on classification performance was investigated 
and overall it was found that employing oversampling and threshold moving indeed 
had a positive impact on obtaining accurate classifiers. 
isoCYP207 is a software tool for the prediction of human CYP isoform specificity 
based on the work of Terfloth et al.,208 who developed a number of classification 
models using multinomial logistic regression, decision trees and SVM. The models 
are trained on a set of 146 compounds known to be metabolized by human CYP3A4, 
2D6 and 2C9 isoforms and the models were evaluated using an external validation 
data set comprising 233 compounds. The best model obtained a leave-one-out cross-
validated predictivity of 83% (correct predictions) for the external validation set. 
Another study employing SVM to identify and classify substrates of CYP1A2, 2C9, 
2C19, 2D6, and 3A4 is based on a 17000 compounds data set from the National 
Institutes of Health Chemical Genomics Center (NCGC).209 Classification models 
obtained area under the receiver operating characteristic (ROC) curves equal to or 
higher than 0.85 for any of the investigated CYP isoforms. 
Quantitative models 
While classification models are sometimes preferred to numerical/regression 
models since they often have superior performance in validation experiments when 
only class labels are required, they are generally not able to make affinity predictions, 
which are at least in relative terms often needed when considering competing 
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interactions in biological systems. Some of those quantitative models relating to 
metabolism prediction shall be discussed below. 
Classical quantitative QSAR models 
Lewis et al.210 established quantitative models for ligands for a total of six P450 
isoforms, namely CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4. In this work the authors 
obtained correlation coefficients ranging from R = 0.94 to 0.99 between predicted and 
experimental P450 binding affinity, which in this case included a mixture of Km, Kd 
or Ki values. They found that including hydrogen bonding parameters in the QSAR 
analysis in combination with the number of pi-pi stacking interactions was crucial for 
model performance. Hence, given that interpretable variables were employed in the 
model in the first place, knowledge about interactions could also be derived – to some 
extent – from the resulting model. 
For the isoforms CYP2D6, 1A2, 3A4, 2A6, 2C9, 2C8, 2C19 and CYP17, PLS 
regression as well as 18 machine learning methods as implemented in WEKA211 were 
recently employed on a dataset comprising a total of 797 ligand-CYP IC50 
datapoints.212 PLS regression as a baseline method was employed on a subset of six 
and 15 selected descriptors, respectively. From the resulting models, R2 values from 
0.69 to 0.94 were obtained for the six-descriptor subset, and from 0.78 to 0.99 for the 
set comprising 15 descriptors, respectively. However, a particular modeling 
technique, namely PLS “with mixed-integer linear programming based hyperboxes”, 
was able to improve upon those results using only six descriptors. The method 
involved homology modeling, docking, and finally ligand-based classification steps 
which likely renders it time-intensive in practice. Also the descriptors selected to be 
the most significant are largely non-interpretable connectivity indices which are not 
generally intuitively related to metabolic mechanisms. 
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In a similar fashion, the way data for CYP inhibition or substrate-likeness data are 
obtained experimentally can have a profound impact on the performance and 
applicability of CYP SAR models. In a recent study,213 the data sets consisted of 
marketed drugs and drug-like compounds all tested in four assays measuring the 
inhibition of the metabolism of four different substrates by the CYP3A4 enzyme, 
benzyloxycoumarin, testosterone, benzyloxyresorufin, and midazolam. It was found 
that by employing only a single one of the four datasets no reliable inhibition model 
could be generated. On the full dataset however, a multiple pharmacophore 
hypothesis could be developed which was able to model promiscuity, in particular the 
CYP3A4 isoform of the CYP family. Hence, care should be paid not only to the 
statistical model validation method employed, but also to the data used to generate 
models for P450 activity. 
As a commercial software provider, ACD has a software suite on the market that is 
able to make regioselective predictions of metabolic transformations in its P450 
Regioselectivity Module.214 Based on more than 900 training set compounds, every 
atom is assigned a likelihood of undergoing one of five possible transformations, 
namely N-dealkylation, O-dealkylation, aliphatic hydroxylation, aromatic 
hydroxylation, S-oxidation. A Reliability Index for the prediction is provided, 
depending on the similarity to the training set atoms as well as the consistency of 
metabolic transformation information. Optionally, isoform-specific predictions can 
also be performed for CYP3A4, 2D6, 2C9, 1A2, and 2C19 using additional software 
modules. However, to the knowledge of the authors no standardized validation of the 
tool has been publicly released. 
In silico tools using different machine learning methods have been derived for 
various enzyme isoforms. For the CYP2D6 and 2C9 isoforms multidimensional 
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QSAR has been employed to quantify the binding affinity of 56 compounds and 85 
compounds, respectively, to their metabolizing enzymes.215 In this study, a cross-
validated R2 of 0.81 and 0.69 was obtained, and models were validated by different 
methods including Y scrambling and an additional external test set. This model is also 
available publicly at VirtualToxLab, which combines multi-dimensional QSAR with 
a flexible docking approach.216 
VirtualToxLab supplies QSAR models for 16 proteins known or suspected to be 
responsible for adverse drug effects, including AhR, androgen receptor (AR), 
estrogen receptor (ER), etc., and reports a calculated toxic potential.216 It was used to 
predict the toxic potential of more than 2000 xenobiotics and chemicals and to 
estimate the binding affinities of anthracene- and steroid-based compounds on various 
CYP isoforms and on AhR (see below). 
3D-QSAR and molecular interaction fields 
3D-QSAR analyses such as Comparative Molecular Field Analysis (CoMFA),217 
GRID/Generating Optimal Linear PLS Estimations (GOLPE)218 and GRid alignment 
INDependent (GRIND) approaches have been employed to predict interaction 
partners of CYP enzymes. CoMFA as well as GRID descriptors depend on the 
alignment of molecules, which is problematic for many 3D-QSAR applications, as 
ligand alignment is non-trivial and time-consuming and induces a bias into the model. 
GRID alignment independent descriptors have been developed to overcome these 
shortcoming.219, 220 They are derived from MIFs by a data compression process that 
elucidate the most-relevant interaction regions of a molecule. GRIND descriptors are 
independent from the orientation of the molecule and hence only the internal 
coordinates of interaction patterns are encoded. Most importantly, GRIND descriptors 
can be back-converted into the primary MIF descriptors by an autocorrelation 
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transform, which allows visualization and interpretation of data in the original 3D 
space. The ALMOND220 software package allows the calculation, analysis and 
interpretation of GRIND descriptors. It has recently been superseded by Pentacle.221 
Classification Models. Crivori et al.222 trained a classification model for the 
prediction of the metabolic stability of small organic molecules to CYP3A4 
combining GRIND descriptors with VolSurf, a MIF-based program to calculate 
pharmacokinetic properties of small organic molecules.223 The training set consisted 
of 1800 from the Pharmacia compound collection. The model derived using these data 
obtained a correct prediction rate of 75% to 85% of the test set compounds, with a 
precision of 86% correctly identified metabolically stable compounds. A further study 
reporting classification and regression models for CYP2C9224 is reported in the next 
section. 
Regression Models. CoMFA and GRID/GOLPE regression models were reported 
for CYP1A2 inhibition, based on a consistently assembled dataset of 52 compounds 
comprising different scaffolds.225 CoMFA models yielded a Q2 of 0.69 (five-fold 
cross validation) and R2 of 0.87, GRID/GOLPE yielded a Q2 of 0.79 and R2 of 0.90, 
respectively. In a similar approach, a CoMFA model for CYP2B6 inhibition226 was 
prospectively validated, which led to the discovery of three potent pyridine-based 
novel CYP2B6 inhibitors. For a CYP2D6 isoform model based on the CoMFA 
method, a training set of 24 compounds with reported Km values was developed 
which achieved a predictive R2 of 0.62. 
CoMFA/GOLPE models were also obtained for 50 steroid inhibitors of CYP19 
(aromatase). The CoMFA fields are consistent with known, potent inhibitors of 
aromatase, not included in the model (R2 of 0.885, cross-validated Q2 of 0.673).227 In 
a similar fashion, the CYP2A5 and 2A6 isoforms were analyzed using CoMFA and 
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GRID/GOLPE.228 From this work, it was suggested that the CYP2A5 binding site is 
likely larger than that of CYP2A6, as indicated by larger steric regions in the CoMFA 
coefficient arrays as well as a similar view of the corresponding GOLPE maps. From 
an analysis of electrostatic maps, it was deduced that CYP2A6 disfavors a negative 
charge near the lactone moiety of coumarin, which was in agreement with available 
data. 
The GRID/GOLPE approach was also successfully employed to derive a 3D-QSAR 
model for CYP2C9 inhibitors.229 In this study, the selection of ligand conformers was 
guided by docking a set of ligands to a CYP2C9 homology model employing GOLD. 
Following up on their prior effort, Afzelius et al.224 used a more diverse dataset to 
create regression (and classification models) for CYP2C9 inhibitors. The high 
diversity of the data, including ligands of MW 100-1000, rendered the elucidation of 
specific alignment rules unfeasible and lead to the application of a GRIND-based 
approach using ALMOND. In this study, 74% of the compounds of an external test 
set could be correctly classified. A subsequently derived quantitative model was able 
to predict the Ki values within half a log unit for the vast majority of compounds. This 
work was again extended by adapting the CORE method developed by Goodford230 to 
handle ligand flexibility in order to account for ligand movement during the approach 
to the ligand binding site. Using this method the relevant conformational space is 
encoded in the form of a probability-of-interaction map. The resulting MIFs were 
transformed into GRIND descriptor values using ALMOND. The experimental Ki 
values of eleven out of twelve compounds representing the external test set were 
predicted within half a log unit by this confomer- and alignment-independent QSAR 
model. 
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A further 3D-QSAR study compared the GRID/GOLPE approach with 
COMparative BINding Energy (COMBINE) analysis, an approach that analyses a 
series of structures of protein-ligand complexes to derive 3D-QSAR models.231 It was 
found that, provided an appropriate alignment is used for model generation, the 
derived interaction patterns are largely consistent with each other. 
A GRIND-based 3D-pharmacophoric model for CYP3A4 was reported by 
Cianchetta et al.232 A dataset of 331 compounds with inhibition data available for 
CYP3A4 was used to derive a 3D-QSAR model from MIFs. In parallel, GRIND 
descriptors were also calculated for four CYP3A4 crystal structures and subsequently 
compared with the pharmacophore model derived from the ligands. A clear 
correlation between the 3D-QSAR model and the MIFs generated from the 
experimental protein structures was found and three features crucial for binding 
affinity, two hydrophobic areas and one hydrogen-bond acceptor, were revealed. 
Classic pharmacophore-based approaches 
Interactions of ligands with biomolecules are driven by the complementarity of 
global and local physicochemical properties. Detection and analysis of patterns 
among ligands, the receptor, and ligand-receptor complexes form the fundamental 
basis for rational drug design. A pharmacophore defines a pattern of chemical and 
steric features essential for the interaction of a ligand with its receptor. The robustness 
of the approach infers from its simplicity. Only a very few feature types are required 
to characterize most of the commonly observed protein-ligand interaction types, such 
as hydrogen bond donors/acceptors, aromatic interactions, hydrophobic interactions, 
ionic and metal interactions. These are usually depicted as colored spheres, disks or 
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graphs, and directed features (hydrogen bonding, pi-stacking and metal binding 
features) generally include a vector to indicate their orientations, if determinable. 
Classic pharmacophore models are derived in a ligand-based or structure-based 
approach. For the ligand-based approach the ligands are superimposed based on 
matching chemically similar moieties, while for the structure-based approach analyses 
of the receptor or receptor-ligand complexes are used to derive pharmacophore 
models. In cases where the target itself or target structure are unknown or not 
amenable, ligand-based techniques are typically the only approaches available. 
Development of a pharmacophore model is an iterative process, attempting to 
derive the optimum selection of ligands, chemical features and geometric constraints 
during the model training phase. Rigid templates are particularly favorable for ligand-
based modeling, as they allow the conformational degrees of freedom to be narrowed 
down. Once the model has been validated, large-scale virtual screening is rapid. 
Pharmacophore models allow qualitative and quantitative predictions on the 
metabolism of small organic molecules. A pharmacophore model can only cover the 
chemical space considered for training of the model and, as a matter of fact, only a 
particular binding mode. This is in contrast to protein-ligand docking, where the 
protein-ligand interaction motifs are taken as a global model of the receptor. In 
general, the limitation of pharmacophore models to a specific binding mode is 
unlikely to affect the applicability of this approach. If required, multiple 
pharmacophore models can be constructed to account for the different interaction 
patterns. However, in the case of highly promiscuous binding sites such as in 
CYP3A4 this may be a limiting factor.78 
Plasticity of the binding site can be reflected in classical pharmacophore models in 
part by adjustment of tolerances surrounding the pharmacophore feature points. For 
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example, molecular dynamics simulations can be used to quantify and characterize 
target flexibility at an atomic level of detail. These observations can then be included 
in pharmacophore models for scoring of the fitness of molecules to the 
pharmacophoric constraints. 
Reported pharmacophore models have been summarized in a number of 
comprehensive reviews,176, 233-237 and therefore only a brief overview is presented 
here. 
Qualitative and quantitative pharmacophore models have been developed for the 
classification/prediction of substrates and inhibitors of all CYP isoforms important to 
drug discovery, including CYP1A2, 2A6, 2B6, 2C9, 2D6, 3A4, 3A5 and 3A7. For 
example CYP2D6 includes a characteristic positive charge about 5 - 7 Å distant from 
the oxidation site as well as an aromatic interaction.233 Various pharmacophore 
models were proposed with respect to the underlying metabolic reaction.233, 236 Most 
of the CYP2C9 pharmacophore models include a hydrophobic/aromatic and a 
negatively charged interaction area.233, 238 However, non-anionic substrates of 
CYP2C9 are known,239 which illustrates the possibility of bias introduced into a 
pharmacophore model by the training data. In contrast to CYP2C9, 3A4 appears to 
have no obvious specific pharmacophoric requirements. This isoform has often been 
reported as being a particularly challenging target for computational approaches, but 
at the same time, it is the most important CYP for xenobiotic metabolism.176 Schuster 
et al.240 have reported a collection of eleven structure-based and ligand-based 
pharmacophore models for the identification of substrates and inhibitors binding to 
various CYP isoforms. 
70 
A single pharmacophore model cannot characterize a promiscuous ligand binding 
site. Mao et al.213 have shown for CYP3A4 that the generation of several local models 
trained on distinct datasets performs best. 
Overall, pharmacophore-based methods have contributed significantly to the 
understanding of CYP ligand binding. They are powerful, accurate tools for local 
predictions, driving lead optimization and rapid pre-filtering. Their moderate 
capabilities to reflect the global characteristics of promiscuous, highly plastic 
interaction sites may limit their applicability in CYP modeling. 
Protein-ligand docking 
Protein-ligand docking can be used for predicting the binding mode of small 
organic molecules to their target as well as providing an estimate of the binding 
affinity, although most docking tools estimate the geometry of binding with a scoring 
function that is relevant to only this property and not to binding affinity. The ligand 
and protein conformations used as a starting configuration can be decisive for a 
docking algorithm. 
Docking has also been successfully applied to predict and rationalize drug-drug 
interactions on CYP2D6. Twenty established drugs were investigated for their ability 
to bind to a homology model of CYP2D6. Out of the thirteen drugs predicted to 
inhibit this CYP, eleven were experimentally confirmed. In the course of this study, 
an aromatic N-hydroxy metabolite of metoclopramide, a drug to treat nausea and 
vomiting, was identified and experimentally confirmed.241 
Using the same isoform, docking via AutoDock into CYP1A2 homology models 
has been performed, followed by COMBINE and GRID/GOLPE analyses of twelve 
heterocyclic amines. In this case it was found that including structural information for 
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the alignment of compounds did indeed improved model performance, in agreement 
with previous findings.242 
Combined approaches for interaction prediction 
Leong et al.243 used a pharmacophore ensemble/SVM approach to increase the 
predictive power of a model for CYP2A6 interaction. Protein flexibility was 
simulated by employing three individual pharmacophore models. 
An interesting method employing MIFs is the proteochemometric analysis of CYP 
sequences to relate these to the activity of inhibitors.244 Using this approach, 
Kontijevskis et al. aimed to establish a general model for the prediction of isoform-
specific inhibition rates and to gain knowledge about properties of the different CYP 
isoforms and their inhibitors. A dataset of 375 structurally diverse inhibitors with 
reported IC50 values for 14 different CYP isoforms was collected and GRIND 
descriptors were calculated for all of these small organic molecules. The protein 
sequences of 14 CYP isoforms were aligned and analyzed for characteristic patterns. 
Six groups of aligned amino acid positions showed the same variance throughout the 
sequence alignment. These groups consist of two or more amino acid positions with 
binary sequence variability, encoded in binary descriptor values. Similar descriptors 
were also created for 20 additional amino acid positions that differed between two 
amino acids, but without co-variation with any other sequence position. Finally, the 
remaining 388 amino acid positions were encoded by five z-scale properties,245 which 
represent principal components for a set of measured physicochemical properties of 
amino acids. Principal component analysis (PCA) was employed to reduce the 
number of descriptors for both CYPs and ligands, cross-terms were generated to 
describe ligand-CYP interactions, and PLS was applied for generation of the models. 
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Results of the model validation indicated a RMSD of prediction of 0.65 to 0.81 for the 
prediction of new ligand data on the investigated 14 CYP isoforms. Novel insights 
into SARs derived from the MIF-based analysis may help designing drugs with 
favorable metabolic profiles. The method could also be used for fast metabolic 
profiling in virtual screening. 
Bazeley et al.246 analyzed the binding affinity of substrates of CYP2D6 using a 
combination of machine learning, protein modeling and protein-ligand docking 
algorithms. Structural models of various CYPs were aligned and analyzed for 
structurally conserved regions, which were conformationally preserved during 
subsequent simulated annealing runs. This resulted in twenty distinct protein 
conformations reflecting the flexibility of CYP2D6. 82 small organic molecules with 
known affinities for CYP2D6 were docked to these protein conformations. The 
docking scores were used as attributes for ANN model generation. Also compound-
specific descriptors were calculated and employed as attributes for model building. 
The best performing, optimized ANN model gave a prediction accuracy of 85%. 
Attribute selection for the ANN model identified docking scores of three of the 20 
protein conformations as being dominant for the predictability of binding affinity. 
From the ligand perspective, the number of positive charges, ALogP and the number 
of aromatic rings were identified as the most important descriptors. 
VirtualToxLab247 uses a combination of multi-dimensional QSAR and flexible 
docking for the prediction of the interactions of small organic molecules with 16 anti-
targets, including CYP450 1A2, 2A13, 2C9, 2D6 and 3A4. Interactions of query 
molecules with any of the 16 target structures can be visualized. 
Predicting CYP induction by xenobiotics 
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CYP induction is caused by either an amplified de novo synthesis of the protein or, 
less frequently, by a decelerated enzyme degradation pathway.5 Depending on the 
CYP isoform involved in DDIs, enzyme induction can cause minor to substantial 
clinical effects.177 CYP isoforms known to be induced in humans include CYP1A, 
2A, 2B, 2C, 2E1 and 3A.248 
Nuclear receptors are a primary control mechanism for gene transcription and, 
hence, a molecule that activates a nuclear receptor may function as an enzyme 
inducer. Among the nuclear receptors most important for the transcription of CYPs 
are the aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), and 
pregnane X receptor (PXR).5, 177 These are also referred to as xenobiotic-activated 
receptors (XARs). They are known to be highly promiscuous sensors, binding a set of 
structurally diverse xenobiotics, in particular those that are hydrophobic.182 For 
example, PXR binds rifampicin, dexamethasone, bosentan and artimisinin 
antimalarials. Additionally, the peroxisome proliferator activated receptor (PPAR) 
and the glucocorticoid receptor (GR) have also been shown to mediate CYP enzyme 
expression7 and inducing xenobiotics have been reported to bind to the hepatocyte 
nuclear factor-4α (HNF4α) and the vitamin D receptor.182 For more detail on 
xenobiotic inducers of CYPs, the interested reader is referred to excellent review on 
modeling CYP substrates, inhibitors, activators and inducers by de Lisle et al.249 
In silico methods have been reported for many of these receptors but their 
promiscuity, resulting from their flexibility, their extended binding pockets and their 
non-specific, lipophilic interaction features make them challenging targets. A number 
of in silico methods in particular struggle with the problem of multiple binding modes 
for one target. In the case of pharmacophore models, individual models generally 
need to be created for each binding mode. 
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Pregnane X receptor (PXR) 
PXR is one of the key xenobiotics sensing enzymes regulating the expression of 
CYP 3A4.248 It is known for its promiscuity, being able to accommodate a large range 
of diverse chemical compounds within the binding site. Single ligands can be 
observed to bind in multiple modes, which adds to the complexity of understanding 
the binding of antagonists at this receptor. Xue et al.,250 who aimed to develop 
antagonists by introducing sterically hindering moieties to known agonists, were 
unable to find any, due to the enormous promiscuity of this protein. 
QSAR studies including a PLS approach in combination with VolSurf descriptors 
have been used to derive models for ligands of human PXR and AhR.251 Ung et al.252 
employed the machine learning methods SVM, k-nearest neighbor and probabilistic 
neural network (PNN) for classifying activators and non-activators. Prediction 
accuracy rates for a 10-fold cross validation test were found in the range of 61% to 
87%, depending on the compound class (activators and non-activators). 
Also, a number of pharmacophore-based studies have been reported that aim to 
derive models identifying compounds binding to PXR (see Refs. 253-255). These 
models in general include three to five hydrophobic areas as well as one or two 
hydrogen bonding features. Yasuda et al.256 used several pharmacophore models 
published in earlier studies to assess their potential in predicting PXR activators. They 
found two of these pharmacophore models obtained reasonable prediction accuracy, 
while the model based on the most diverse training set had inferior performance. This 
is likely to be caused by the presence of more than one binding mode, which cannot 
be adequately covered by a single model. Intriguingly, dicloxacillin was found to be 
the only PXR binder that could be successfully mapped with any of the three 
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investigated pharmacophore models. The authors also employed the docking software 
FlexX to investigate the binding of known activators to PXR. 
Gao et al.257 introduced new hydrophilic moieties to PXR activators to lower their 
activity on this receptor. The optimization strategies were developed from results of a 
protein-ligand docking approach.  
In a recently published study assessing the performance and reliability of PXR, 
using in vitro assays and in silico modeling approaches, the physicochemical 
properties of 37 marketed drugs and their interaction with PXR were examined.258 
The computational analyses pointed out that descriptors for molecular weight and 
shape of a ligand are decisive for its potential to bind to PXR. Compounds of 
molecular weight lower than 300 as well as compounds that have a molecular shape 
which does not correspond to the inverse shape of the protein binding site are unlikely 
to exhibit activity. Strong binders show favorable hydrophobic interactions and 
hydrogen bonding features within the binding pocket, as observed during docking 
studies using GLIDE.53 Binding promiscuity is facilitated by the flexibility of the 
protein but also by the conformational space accessible to the binders. 
Aryl hydrocarbon receptor (AhR) 
AhR is a cytosolic transcription factor that is a key regulator for CYP1A1 and 
CYP1A2 in humans.248 Besides the induction of these CYP isoforms, AhR signaling 
also induces a number of other enzymes including UDP-glucuronosyltransferase 1A 
(UGT1A1) and glutathione S-transferase A2 (GSTA2). 
In addition to the QSAR models for human AhR and PXR presented above, recent 
examples include the work of Bisson et al.,259 who derived homology models of the 
AhR PAS domain to investigate intra- and inter-species differences in ligand binding 
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using Internal Coordinate Modeling ICM.260 Amongst other observations, their 
approach led to the successful identification of two flavonoids, pinocembrin and 5-
hydroxy-7-methoxyflavone, which are experimentally shown to be promoters of 
nuclear translocation and transcriptional activation of AhR and AhR-dependent 
induction of endogenous target genes. As an example of an implementation in a 
commercial software product, a model for the prediction of ligand activity on AhR is 
included in VirtualToxLab. 
Constitutive androstane receptor (CAR) 
The constitutive androstane receptor (CAR) is responsible for the induction of 
CYP2B6, which is a key enzyme for the metabolism of a large number of drugs 
including human immunodeficiency virus (HIV) therapeutics, chemotherapeutics and 
opioids.248 
Using a pharmacophore-based approach, CAR ligands were reported to show planar 
structures with a hydrogen bond acceptor and two to three hydrophobic areas.261 
Jyrkkärinne et al.262 used pharmacophore-based virtual screening to identify novel 
agonists of CAR and employed these data to develop a GRID/GOLPE-based 3D-
QSAR model in an attempt to explain activity of compounds on CAR. For a leave-
20%-out validation method, the model obtained a q2 value of 0.68 and a standard 
error of prediction of 0.93. Further to that, docking studies of CAR agonists on the X-
ray structure of human CAR revealed several key interactions for ligand binding. 
More recently, homology models derived for CAR, AhR, and PXR (all in the rat) 
were used as a structural basis for docking a number of organic pollutants such as 
polybrominated dibenzofurans and polybrominated diphenyl ethers to these nuclear 
hormone receptors, with the aim of identifying potential binders to these proteins.263 
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The results of this retrospective study were found to be in agreement with results of 
experiments and suggest that such structure-based modeling methods represent 
valuable tools for the evaluation of effects of small organic molecules on nuclear 
hormone receptors. 
PERSPECTIVE AND OUTLOOK 
Metabolic properties are decisive for the discovery, development and market 
success of drugs, nutritional supplements and agrochemicals. Interactions of 
xenobiotics with key metabolizing enzymes may lead to considerable changes in 
kinetics, which may cause toxic effects or failure of action. Genetic polymorphism 
adds another layer of complexity to the problem. 
Numerous drug candidates and agrochemicals have failed in the past and novel 
entities are still failing because of unfavorable metabolic profiles, despite substantial 
efforts being made in industry to predict such problems early and to develop strategies 
to counter them. 
A plethora of computational methods, both ligand-based and structure-based have 
been developed, which can provide decisive insights on the metabolic fate of 
xenobiotics. They allow the prediction of likely sites of metabolism (SOMs), the 
chemical structure of potential metabolites and inhibition and induction of key 
enzymes involved in xenobiotic metabolism. For all of these areas of research, a 
number of success stories have been published, as discussed in this review. 
The complexity of predicting xenobiotic metabolism suggests that one particular 
algorithm will not show superior performance in all of the three domains discussed 
here. Rather, the combination of techniques is most promising to lead to valid 
conclusions. 
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SOM prediction is feasible, with state-of-the-art computational methods 
successfully identifying SOMs among the three highest-ranked atom positions in a 
range of 70-90% for most cases. Even though relative ranking of atom positions is 
feasible, current methods do not make accurate predictions for the absolute likelihood 
of a certain biotransformation. This limitation makes it difficult if not impossible to 
draw any quantitative conclusions on the metabolic liability of a certain molecule and, 
hence, to compare different molecules with respect to their metabolic stability. In 
particular, the combination of individual methods covering different aspects of the 
biotransformation process could be expected to lead to a potential boost in prediction 
accuracy. Systems biology approaches (not reviewed here) have a major contribution 
to make, by incorporation of multiple models which take into account not only the 
likelihood of metabolism at a site in a molecule at a specified rate, but also the 
molecules bioavailability and concentration at the tissue site of metabolism. A much 
more complicated scenario. 
Knowledge-driven approaches such as expert systems and data mining techniques 
allow extrapolation of the structure to likely metabolites. Most challenging in this 
domain is addressing the combinatorial explosion problem, which arises from the 
virtually unlimited possibilities for processing generations of metabolites. Advanced 
reasoning rules and knowledge-based potentials considered for metabolite ranking, as 
well as consideration of physicochemical properties of the generated metabolites 
(such as logP) attempt to address this problem as well as possible. 
Also, a respectable number of computational approaches have been developed and 
applied to the prediction of direct and indirect interactions of xenobiotics with key 
metabolic enzymes. CYPs represent the primary focus of research and inhibition of 
this enzyme family has been successfully predicted by a variety of computational 
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approaches including (3D)-QSAR and machine learning methods, pharmacophore- 
and docking-based approaches, as well as combinations of these. The expression of 
CYPs is steered by nuclear receptors such as PXR, AhR and CAR, to which similar 
methodologies have been applied, but to a lower extent. 
Methods developed in academia all too often lack maturation of the promising 
concepts they are based upon or an implementation of these algorithms into accessible 
-in the best case- user-friendly software packages. Tools freely available to the 
scientific community are still scarce. Further, the limited data related to metabolism 
(experimentally-derived SOMs, structures of metabolites, enzyme inhibition and 
induction data) are a bottleneck for method development. However, recent major 
releases of bioactivity data to the public, such as ChEMBL,264 World Of Molecular 
BioAcTivity (WOMBAT)265 and others,199 give promising indications of a paradigm 
shift in the scientific community, fostering the open publication of experimental data. 
Also with regard to structure-based approaches there is still enormous potential left 
for further development. Even though several crystal structures of a variety of CYPs 
have become available, their numbers are not sufficient to adequately represent, in 
particular, flexibility of the enzyme catalytic site, though homology modeling and 
MD simulation techniques can help to overcome some of these limitations. For 
instance, for the development of agrochemicals it would be of utmost importance to 
have structures available of pest species. Expeditious technological progress in 
structure determination will improve this situation in the future and make enzyme-
focused methods other than CYPs even more powerful and important. An improved 
data situation will also contribute to solving cardinal problems of structure-based 
approaches, such as target flexibility (in particular for CYPs), solvent, entropic effects 
and, as a consequence, affinity and rate of reaction prediction. 
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However, it is not expected that computational methods will substitute in vitro and 
in vivo methods in the foreseeable future. In fact, it is crucial for the generation of 
computational models to be based on further enhanced assay technology. 
Computational methods are still limited by the reliability of assay systems and the 
information content of the read out. 
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ABBREVIATIONS 
ADME absorption, distribution, metabolism and excretion 
AhR aryl hydrocarbon receptor 
AMBER Assisted Model Building with Energy Refinement 
ANN artificial neural network 
ANNC artificial neural network classification 
ANNE artificial neural network ensemble 
CAR constitutive androstane receptor 
CHARMM Chemistry at HARvard Molecular Mechanics 
COMBINE COMparative BINding Energy 
CoMFA Comparative Molecular Field Analysis 
CYP cytochrome P450 
DDI drug-drug interaction 
DFT density functional theory 
EPR electron paramagnetic resonance 
FEP free energy perturbation 
FF force field 
GLIDE Grid-based LIgand Docking with Energetics 
GRIND GRid alignment INDependent 
GOLD Genetic Optimization for Ligand Docking 
GOLPE Generating Optimal Linear PLS Estimations 
GSTA2 glutathione S-transferase A2 
HIV human immunodeficiency virus 
ICM Internal Coordinate Modeling 
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KEGG Kyoto Encyclopedia of Genes and Genomes 
k-NN k-nearest neighbor 
LC liquid chromatography 
LIE linear interaction energy 
MAO monoamine oxidase 
MC Monte Carlo 
MD molecular dynamics 
MDEA (R)-3,4-methylenedioxy-N-ethylamphetamine 
MIF molecular interaction field 
MM molecular mechanics 
MS mass spectrometry 
NADPH nicotinamide adenine dinucleotide phosphate 
NCE novel chemical entity 
NCGC National Institutes of Health Chemical Genomics Center 
OECD Organisation for Economic Co-operation and Development 
PCA principal component analysis 
PLOP Protein Local Optimization Program 
PLS partial least squares 
PME Particle Mesh Ewald 
PNN probabilistic neural network 
PXR pregnane X receptor 
QM quantum mechanics 
QM/MM quantum mechanics/molecular mechanics 
QSAR quantitative structure-activity relationship 
RAMBA retinoic acid metabolizing blocking agent 
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RMSD root mean square deviation 
RMSF root mean square fluctuation 
ROC receiver operating characteristic 
ROCS rapid overlay of chemical structures 
RS-predictor RegioSelectivity predictor 
SAR structure-activity relationship 
SASA solvent-accessible surface area 
SMARTS SMiles ARbitrary Target Specification 
SOM site of metabolism 
SVM support vector machine 
SyGMa Systematic Generation of potential Metabolites 
TI thermodynamic integration 
TIMES TImes MEtabolism Simulator 
UGT1A1 UDP-glucuronosyltransferase 1A 
UM-BBD University of Minnesota Biocatalysis/Biodegradation Database 
UM-PPS University of Minnesota Pathway Prediction System 
WOMBAT World Of Molecular BioAcTivity 
XAR xenobiotic-activated receptor 
84 
ACKNOWLEDGEMENT 
JK, MJW, JT, PJB, AB and RCG thank Unilever for funding.  
REFERENCES 
1. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. 
Drug Discovery 2009, 8, 959-968. 
2. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. 
Drug Discovery 2011, 10, 507-519. 
3. Mahmood, M.; Malone, D. C.; Skrepnek, G. H.; Abarca, J.; Armstrong, E. P.; 
Murphy, J. E.; Grizzle, A. J.; Ko, Y.; Woosley, R. L. Potential drug-drug interactions 
within veterans affairs medical centers. Am. J. Health-Syst. Ph. 2007, 64, 1500-1505. 
4. Yeung, C. K.; Fujioka, Y.; Hachad, H.; Levy, R. H.; Isoherranen, N. Are 
circulating metabolites important in drug-drug interactions?: Quantitative analysis of 
risk prediction and inhibitory potency. Clin. Pharmacol. Ther. 2011, 89, 105-113. 
5. Almond, L. M.; Yang, J.; Jamei, M.; Tucker, G. T.; Rostami-Hodjegan, a. 
Towards a quantitative framework for the prediction of DDIs arising from 
cytochrome P450 induction. Curr. Drug Metab. 2009, 10, 420-432. 
6. Hewitt, N. J.; Lecluyse, E. L.; Ferguson, S. S. Induction of hepatic cytochrome 
P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo 
correlations. Xenobiotica 2007, 37, 1196-1224. 
7. Sun, H.; Scott, D. O. Structure-based drug metabolism predictions for drug 
design. Chem. Biol. Drug. Des. 2010, 75, 3-17. 
8. Jones, S. L.; Athan, E.; O'Brien, D. Serotonin syndrome due to co-
administration of linezolid and venlafaxine. J. Antimicrob. Chemoth. 2004, 54, 289-
290. 
9. Sullivan, E. A.; Shulman, K. I. Diet and monoamine oxidase inhibitors: A re-
examination. Can. J. Psychiatry. 1984, 29, 707-711. 
10. Gillman, P. K. Monoamine oxidase inhibitors, opioid analgesics and serotonin 
toxicity. Brit. J. Anaesthesia 2005, 95, 434-441. 
11. Lotfipour, S.; Arnold, M. M.; Hogenkamp, D. J.; Gee, K. W.; Belluzzi, J. D.; 
Leslie, F. M. The monoamine oxidase (MAO) inhibitor tranylcypromine enhances 
nicotine self-administration in rats through a mechanism independent of MAO 
inhibition. Neuropharmacology 2011, 61, 95-104. 
12. Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J. 
W.; (Eds.). Prodrugs: Challenges and rewards, part 1. Springer: New York, NY, 
2007; Vol. 5. 
13. Tarcsay, Á.; Keseru, G. M. In silico site of metabolism prediction of 
cytochrome P450-mediated biotransformations. Expert Opin. Drug Metab. Toxicol. 
2011, 7, 299-312. 
14. Kirchmair, J.; Markt, P.; Distinto, S.; Schuster, D.; Spitzer, G. M.; Liedl, K. 
R.; Langer, T.; Wolber, G. The Protein Data Bank (PDB), its related services and 
software tools as key components for in silico guided drug discovery. J. Med. Chem. 
2008, 51, 7021-7040. 
85 
15. Zaretzki, J.; Bergeron, C.; Rydberg, P.; Huang, T.-W.; Bennett, K. P.; 
Breneman, C. M. RS-Predictor: A new tool for predicting sites of cytochrome P450-
mediated metabolism applied to CYP 3A4. J. Chem. Inf. Model. 2011, 51, 1667-1689. 
16. Afzelius, L.; Arnby, C. H.; Broo, A.; Carlsson, L.; Isaksson, C.; Jurva, U.; 
Kjellander, B.; Kolmodin, K.; Nilsson, K.; Raubacher, F.; Weidolf, L. State-of-the-art 
tools for computational site of metabolism predictions: Comparative analysis, 
mechanistical insights, and future applications. Drug Metab. Rev. 2007, 39, 61-86. 
17. Hennemann, M.; Friedl, A.; Lobell, M.; Keldenich, J.; Hillisch, A.; Clark, T.; 
Göller, A. H. CypScore: Quantitative prediction of reactivity toward cytochromes 
P450 based on semiempirical molecular orbital theory. ChemMedChem 2009, 4, 657-
669. 
18. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development 
and use of quantum mechanical molecular models. 76. AM1: A new general purpose 
quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909. 
19. Materials studio - VAMP software module, version 6.0; Accelrys: San Diego, 
CA, 2011. 
20. ParaSurf, version 11; Cepos InSilico: Bedford, United Kingdom, 2011. 
21. Adams, S. E. Molecular similarity and xenobiotic metabolism. Ph.D. Thesis, 
University of Cambridge, Cambridge, United Kingdom, 2010. 
22. Boyer, S.; Arnby, C. H.; Carlsson, L.; Smith, J.; Stein, V.; Glen, R. C. 
Reaction site mapping of xenobiotic biotransformations. J. Chem. Inf. Model. 2007, 
47, 583-590. 
23. Carlsson, L.; Spjuth, O.; Adams, S.; Glen, R. C.; Boyer, S. Use of historic 
metabolic biotransformation data as a means of anticipating metabolic sites using 
MetaPrint2D and bioclipse. BMC Bioinformatics 2010, 11, 362. 
24. MetaPrint2D, version 1.0; Unilever Centre for Molecular Science Informatics, 
University of Cambridge: Cambridge, UK, 2010. 
25. MetaPrint2D. http://www-metaprint2d.ch.cam.ac.uk/metaprint2d (Access date 
2012-01-12). 
26. Accelrys Metabolite Database, version 2011.2; Accelrys: San Diego, CA, 
2011. 
27. MetaPrint2D-react. http://www-metaprint2d.ch.cam.ac.uk/metaprint2d-react 
(Access date 2012-01-12). 
28. ADMET Predictor - Metabolite software module, version 5.5; Simulations 
Plus: Lancaster, CA, 2011. 
29. Carrieri, A.; Pérez-Nueno, V. I.; Fano, A.; Pistone, C.; Ritchie, D. W.; 
Teixidó, J. Biological profiling of anti-HIV agents and insight into CCR5 antagonist 
binding using in silico techniques. ChemMedChem 2009, 4, 1153-1163. 
30. Kirchmair, J.; Distinto, S.; Markt, P.; Schuster, D.; Spitzer, G. M.; Liedl, K. 
R.; Wolber, G. How to optimize shape-based virtual screening: Choosing the right 
query and including chemical information. J. Chem. Inf. Model. 2009, 49, 678-692. 
31. Kirchmair, J.; Ristic, S.; Eder, K.; Markt, P.; Wolber, G.; Laggner, C.; Langer, 
T. Fast and efficient in silico 3D screening: Toward maximum computational 
efficiency of pharmacophore-based and shape-based approaches. J. Chem. Inf. Model. 
2007, 47, 2182-2196. 
32. Pérez-Nueno, V. I.; Pettersson, S.; Ritchie, D. W.; Borrell, J. I.; Teixidó, J. 
Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective 
virtual screening. J. Chem. Inf. Model. 2009, 49, 810-823. 
33. Pérez-Nueno, V. I.; Ritchie, D. W.; Borrell, J. I.; Teixidó, J. Clustering and 
classifying diverse HIV entry inhibitors using a novel consensus shape-based virtual 
86 
screening approach: Further evidence for multiple binding sites within the CCR5 
extracellular pocket. J. Chem. Inf. Model. 2008, 48, 2146-2165. 
34. Venkatraman, V.; Pérez-Nueno, V. I.; Mavridis, L.; Ritchie, D. W. 
Comprehensive comparison of ligand-based virtual screening tools against the DUD 
data set reveals limitations of current 3D methods. J. Chem. Inf. Model. 2010, 50, 
2079-2093. 
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TABLES AND GRAPHICS 
Table 1. Overview on Methods for Predicting SOMs, Structures of Metabolites and Interactions with Metabolizing Enzymes. 
Methods for predicting 
SOMs 
Category Description 
References 
(Examples) 
QMBO 
Reactivity-based 
method 
Derives likelihood of a metabolic reaction at a certain atom position from its 
hydrogen abstraction energy based on bond order, employing a DFT 
wavefunction. Considers accessibility of hydrogen atoms. 
16 
CypScore 
Reactivity-based 
method 
Uses AM1-based atom reactivity descriptors to estimate metabolic reactivity 
of a certain atom position. Six models to describe various generic CYP 
metabolic reactions 
17 
Metaprint2D 
Fingerprint-based data 
mining method 
Derives likelihood of metabolic transformations for atoms with a defined atom 
environment from data mining of large biotransformation databases. Encodes 
atom environments using SYBYL266 atom types in combination with circular 
fingerprints 
21-24 
ADMET Predictor – 
Metabolite Module 
Machine learning 
method 
Derives the likelihood of metabolic reactions to happen at specific atom 
positions using ANN ensembles. Classification models allow identification of 
substrates for five CYP isoforms. 
28 
ROCS 
Shaped-focused 
method 
Uses shape-focused alignment of molecules to known CYP substrates in order 
to derive a potential geometric orientation to the catalytic heme iron. Atom 
positions in the proximity of the heme iron are considered potential SOMs 
37 
Classic docking tools 
(AutoDock, FlexX, GLIDE, 
GOLD, etc.) 
Protein-ligand docking-
based method 
Evaluate orientation of the ligand to the enzyme catalytic center in order to 
identify potential SOMs. Atom positions in the proximity of the heme iron are 
considered potential SOMs 
51, 52 
MetaSite Combined approach 
Uses protein structural information, GRID-derived MIFs of protein and 
ligand, as well as molecular orbital calculations to estimate the likelihood of a 
metabolic reaction at a certain atom position 
40, 54, 55 
Combined pharmacophore, 
homology modeling and 
quantum chemical approach 
Combined approach 
Combines a pharmacophore-based approach, homology modeling and 
molecular orbital calculations to pinpoint potential SOMs 
60 
102 
SmartCyp Combined approach 
Utilizes a set of pre-calculated DFT activation energies in combination with a 
topological accessibility descriptors for prognosis of potential SOMs 
(CYP3A4 and 2D6) 
61, 62 
StarDrop Combined approach 
Combines quantum chemical analysis and a ligand-based model of CYP 
substrates to highlight potential SOMs. Takes into account calculated logP 
values 
64 
RS-Predictor Combined approach 
Utilizes a set of 148 topological and 392 quantum chemical atom-specific 
descriptors in combination with a SVM-like ranking and a multiple instance 
learning method to identify potential SOMs 
15 
Machine learning-based 
multi-descriptor approach 
Combined approach 
Takes into account quantum chemical, SASA and pharmacophoric descriptors 
using a random forest/ensemble decision tree approach to identify potential 
SOMs 
65 
Machine learning-based 
multi-descriptor approach 
Combined approach 
Employs electrostatic, inductive, energetic, topological, steric and distance 
properties in combination with a SVM to predict potential SOMs of 
endogenous substrates 
67 
Combined quantum 
chemical/docking/MD 
approach 
Combined approach 
Combination of quantum chemical methods with docking to account for 
reactivity, followed by MD simulations to predict potential SOMs 
69 
MLite Combined approach Combines quantum chemistry-derived reactivity estimation with docking 73 
Ensemble-based/MD-
supported docking 
Protein-ligand docking-
based method 
Accounts for protein target flexibility with conformational ensembles of 
proteins generated using MD simulations and related techniques 
79-82 
IDSite Combined approach 
Combination of an induced fit docking approach (GLIDE, PLOP) with a 
reactivity model (Jaguar) 
84 
Methods for predicting 
xenobiotic metabolites 
Category Description 
References 
(Examples) 
MetabolExpert Expert system 
Uses knowledge database of rules to predict the structures of likely 
metabolites. Predicts pathways in animals, plants or through photodegradation 
88 
META Expert system 
Uses a large dictionary of biotransformations to predict the structure of likely 
metabolites. Analyzes metabolite stability. Predicts pathways in mammals, 
through aerobic and anaerobic biodegradation 
89 
Meteor Expert system 
Employs a collection of knowledge-based biotransformation rules defined 
using a dedicated structure representation language to derive the structure of 
likely metabolites. Considers calculated logP values for predictions 
90 
103 
University of Minnesota 
Pathway Prediction System 
(UM-PPS) 
Expert system 
Utilizes biotransformation rules to predict the structure of likely metabolites. 
Specific to microbial catabolic metabolism 
91 
SyGMa Expert system 
Predicts structures of likely metabolites based on rules derived from the 
Accelrys Metabolite Database and assigns probability scores for each 
metabolite 
92 
TIMES Expert system 
Employs a biotransformation library and a heuristic algorithm to generate 
metabolic maps 
93 
JChem Metabolizer module Expert system 
Enumerates all possible metabolites of a given compound. Supports species-
specific predictions of likely metabolites 
94 
Metaprint2D-React 
Fingerprint-based data 
mining approach 
Predicts structures of likely metabolites based on the MetaPrint2D data 
mining approach 
21 
Machine learning-based 
multi-descriptor approach 
Combined approach See description of this software in “Predicting Sites of Metabolism” 67 
MetaSite Combined approach See description of this software in “Predicting Sites of Metabolism” 40, 54, 55 
Methods for predicting 
CYP binding 
affinity/inhibition by 
xenobiotics 
 Category Description 
References 
(Examples) 
Linear interaction energy 
(LIE) 
MD simulation 
Semi-empirical method for calculating free energy of binding for a ligand 
using ensemble averaged non-bonded interaction energies 
156, 158, 159, 
267 
Free energy perturbation 
(FEP)/thermodynamic 
integration (TI) 
MD simulation 
Simulations of unphysical states along a thermodynamic cycle connecting the 
bound and unbound ligand form for calculating the free energy of binding 
131, 161-163 
Decision tree 
k-nearest neighbor 
ANN 
Random forest 
SVM 
etc. 
QSAR and machine 
learning method: 
Classification model 
Classify compounds for enzyme inhibition. Allow drawing conclusions on 
isoform specificity 
202-206, 209 
isoCyp 
QSAR and machine 
learning method: 
Classification model 
Classifies compounds for CYP3A4, 2D6 and 2C9 inhibition 207, 208 
PCA QSAR and machine Predict inhibition enzyme rates 210, 212-216 
104 
PLS 
Multiple linear regression 
etc. 
learning method: 
Regression model 
CoMFA 
GRID/GOLPE 
3D-QSAR method: 
Classification model 
Classify compounds for enzyme inhibition. Allow drawing conclusions on 
isoform specificity 
222, 224 
CoMFA 
GRID/GOLPE 
3D-QSAR method: 
Regression model 
Predict inhibition enzyme rates. Allow deriving of 3D properties crucial for 
bioactivity 
224-229, 231, 
232 
Pharmacophore models 
Pharmacophore-based 
method 
Predict quantitative and qualitative enzyme inhibition. Allow drawing 
conclusions on isoform specificity 
213, 233, 236, 
238-240 
Protein-ligand docking 
Protein-ligand docking-
based method 
Predict binding mode and binding affinity. Allow drawing conclusions on 
isoform specificity 
159, 241, 242 
Combined pharmacohore 
ensemble/SVM approach 
Combined approach Uses an ensemble of pharmacophores to account for protein flexibility 243 
Proteochemometric analysis 
supported by GRIND and 
further physicochemical 
descriptors 
Combined approach 
Considers protein sequences of 14 CYPs as well as GRIND and further 
descriptors for substrates 
244 
Combined machine learning, 
protein modeling and 
docking approach 
Combined approach 
Uses simulated annealing to render conformational space of the target protein 
and docking scores as attributes for subsequent ANN model generation 
246 
VirtualToxLab Combined approach 
Uses flexible docking in combination with a multi-dimensional QSAR 
approach to predict ligand interaction with 16 anti-targets, including CYP450 
1A2, 2A13, 2C9, 2D6 and 3A4 
247 
Methods for predicting 
CYP induction by 
xenobiotics 
 Category Description 
Examples 
(References) 
PLS using VolSurf 
descriptors 
QSAR approach 
Uses PLS and VolSurf descriptors for the development of a QSAR model for 
PXR/AhR interaction 
PXR: 251 
AhR: 251 
SVM 
k-nearest neighbor 
Probabilistic neural network 
Machine learning 
approach 
Uses various machine learning methods to predict human PXR interaction PXR: 252 
Pharmacophore modeling 
Pharmacophore-based 
method 
Uses pharmacophores to predict PXR/CAR interaction 
PXR: 253-256 
CAR: 262 
Protein-ligand docking 
Protein-ligand docking-
based method 
Uses protein-ligand docking to predict PXR/AhR/CAR activation, rationalize 
SARs and gain insight on likely molecular interaction modes 
PXR: 256-
258, 263 AhR: 
259, 263 
CAR: 263 
GRID/GOLPE 3D-QSAR method Uses MIF-derived 3D-QSAR models to predict CAR interaction CAR: 262 
VirtualToxLab Combined approach 
Uses flexible docking in combination with a multi-dimensional QSAR 
approach to predict ligand interaction with AhR and 15 other targets (see 
above) 
AhR: 247 
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Table 2. Overview on MD Simulation Setups for CYPs. 
Ref FF used Isoforms Heme B parameters used 
Simulation 
time/ns 
Production 
ensemble Comments 
111 AMBER/FF99 CYP2C9 
Developed within their study 5 
(multiple) NPT 
 
114 AMBER/FF99 
CYP2A6, 2C9, 
3A4 
Own charge method with 
parameter taken from Ref. 113 5 NPT 
FF99 used, missing residues in CYP3A4 
(1TQN) 
112 AMBER/FF99 
CYP2C9, 
CYP19 
Refs. 106, 113 
Ferrous low spin state (S=0) 
Fit of heme charges done at 
DFT (B3LYP/6-31G*) level 10 NPT 
Cα RMSD plateaus in phases, culminating at 
~4 Å 
DFT wavefunction used for RESP fitting 
HEME parameters not stated, only the RESP 
charges 
128 CHARMM 27 CYP3A4 Refs. 103, 109 6 NVT Cα RMSD plateaus at ~1.5 Å 
130 AMBER/FF99 
CYP1A2, 2A6, 
2C9, 2D6, 3A4 
Developed within the study 
10 NPT 
FF99 used, missing residues in 3A4 (1TQN) 
Heme parameters provided 
140 GROMOS96 CYPC17 GROMOS96 20 NPT 
Cα RMSD seems high at ~3 Å 
Berendsen thermostat 
137 
CHARMM 27 
(protein) 
CHARMM 22 
(heme) CYP3A4 
CHARMM22 
Refit of heme charges done at 
DFT (B3LYP/MM/LACVP) 
level for sextet state 20 NVT 
Cα RMSD plateaus at ~1.5 Å 
Thorough, with a rich set of supporting 
materials 
139 GROMOS96 CYP3A4 - 5 NPT Cα RMSD plateaus at ~2.5 Å 
124 
AMBER/FF03 
with pi-pi 
stacking term 
modification  CYP2C9 
Developed within their study, 
but used the method of Ref. 110 5 NPT Cα RMSD plateaus at ~2.4 Å 
169 CHARMM27 CYP51 - 20 NPT Cα RMSD not reported 
115 
 
AMBER/ 
FF99SB268 CYP3A4 
Heme parameters for a wide 
range of states developed with 
this study. 25 NPT Cα RMSD plateaus at ~1.7 Å 
122 OPLS CYP119 Heme parameters from Ref. 269 200 NVT 
Longest all atom simulation to date 
RMSD of F/G loop region indicates large 
degree of flexibility 
Berendsen thermostat 
267 
GROMOS 
45A4 CYP1A2 Not stated. 1 NPT  
158 AMBER/FF99 
CYP26A1 and 
CYP26B1 Not stated. 0.5 NVT  
132 CHARM22 CYP101 Heme parameters from Ref. 270 300 NPT  
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Figure 1. Xenobiotic metabolism and its broad spectrum of pharmacodynamic and pharmacokinetic 
effects. Potential issues of metabolic liability and biological activity of xenobiotics on metabolizing enzymes 
include DDIs (in particular, enzyme induction and inhibition), which in turn may cause therapeutic failure, 
toxic and adverse effects. Metabolic reactions can also be exploited for the rational design of prodrugs. 
 
Figure 2. Overview on topics and computational approaches covered in this review. 
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Figure 3. Structural overview of CYPs. Here, CYP3A4 (PDB 3NXU) is depicted, with helical structures 
labeled A-L according to the general scheme for CYPs.96 The heme moiety is indicated in sticks mode (red 
color). 
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